Multimers to reduce interference of drugs binding to CD47 in serological assays
Patent Information
- Application Number
- JP2023533847
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-06
- Filing Date
- 2021-12-06
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-12-06
AI Technical Summary
Antibody-based drugs targeting CD47 can interfere with blood typing and serological assays due to CD47 expression on blood cells, posing a significant patient safety concern, especially in patients requiring blood transfusions.
The use of CD47 multimers or SIRP multimers to bind and block the interaction between drugs and CD47 on reagent red blood cells or platelets in plasma or blood samples, thereby reducing interference in serological assays.
Minimizes drug-induced false positives in serological assays by blocking the binding of drugs to CD47 on reagent cells, ensuring accurate blood typing and transfusion compatibility.
Smart Images

Figure 00000072_0000 
Figure 00000072_0001 
Figure 00000072_0002
Abstract
Description
Technical field
[0001] Cross-reference with related applications This application claims priority to U.S. Provisional Application No. 63 / 121,964, filed December 6, 2020, the contents of which are incorporated by reference in their entirety.
[0002] Submit a sequence listing as an ASCII text file The contents of the following submission as an ASCII text file are incorporated herein by reference in their entirety: Sequence Listing Computer Readable Format (CRF) (File Name: 757972001440SEQLIST.TXT, Date of Record: December 3, 2021; Size:96KB)).
[0003] field of invention The present invention relates to methods and reagents used to reduce interference in serological assays by drugs that include (i) an antibody Fc region and (ii) a portion that binds human CD47. [Background technology]
[0004] The number of antibody-based drugs being developed to treat a wide variety of diseases, including cancer, continues to increase. If the target of the therapeutic antibody is also expressed on blood cells, e.g. red blood cells (RBCs), white blood cells (WBCs), and / or platelets, such treatment may interfere with blood typing and serological assays. there is a possibility.
[0005] For example, CD47, a widely expressed cell surface protein that binds signal regulatory protein alpha (SIRPα) and inhibits phagocytosis (Jaiswal et al., Trends Immunol (2010) 31(6):212-219;Brown et al., Trends Cell Biol (2001) 11(3):130-135) is expressed at high levels on a wide variety of malignant tumors, including hematological and solid tumors. Increased CD47 expression also correlates with progressive disease (Willingham et al., Proc Natl Acad Sci USA (2012) 109(17):6662-6667). Several cancer treatments that target CD47, such as antibodies and fusion proteins containing antibody Fc regions, have been developed to block the SIRPα-CD47 interaction, thereby allowing macrophages to perform phagocytic functions. It becomes possible to perform and remove tumor cells.
[0006] CD47 is also expressed on the surface of blood cells such as red blood cells (RBCs) and platelets (Oldenborg et al., Science (2000) 288(5473):2051-2054). Containing drugs may interfere with blood typing and serological tests. Additionally, patients receiving CD47-targeted drugs (e.g., for the treatment of cancer) often require blood transfusions to treat concurrent anemia and / or thrombocytopenia; Interference with serological and blood typing assays is a significant patient safety concern. Accordingly, there is a need in the art to develop methods and reagents that reduce interference with serological assays of CD47-targeted agents containing antibody Fc regions. [Summary of the invention]
[0007] In some embodiments, a method of reducing drug interference in a serological assay using reagent red blood cells (RBCs) or reagent platelets is provided, the method comprising: (a) binding a drug and the drug binding to the reagent RBCs or platelets; adding a CD47 multimer that blocks binding to reagent platelets to a plasma sample from a subject undergoing treatment with the drug; and (b) using reagent RBCs or reagent platelets after step (a). performing a serological assay of the plasma sample, the drug comprising (i) a human antibody Fc region or variant thereof and (ii) a portion that binds human CD47, the CD47 multimer comprising: Contains at least two CD47 polypeptide monomers.
[0008] In some embodiments, the CD47 multimer comprises 2-100 CD47 polypeptide monomers. In some embodiments, the CD47 multimer comprises a CD47 polypeptide monomer that includes wild-type CD47 or a fragment thereof that is capable of binding a drug. In some embodiments, the CD47 multimer is wild-type human CD47, wild-type mouse CD47, wild-type rat CD47, wild-type rhesus CD47, wild-type cynomolgus monkey CD47, or any of the above, which is capable of binding the drug. Contains a CD47 polypeptide monomer containing one fragment. In some embodiments, the CD47 multimer comprises a CD47 polypeptide monomer comprising the amino acid sequence of SEQ ID NO:1. In some embodiments, the CD47 multimer has one or more amino acid substitutions, insertions, deletions, N-terminal extensions, or C-terminal extensions compared to wild-type CD47 or a fragment thereof that is capable of binding the drug. CD47 polypeptide monomers, including CD47 variants, including CD47 variants. In some embodiments, the CD47 multimer comprises a CD47 polypeptide monomer comprising the amino acid sequence set forth in any one of SEQ ID NOs: 2-6. In some embodiments, a CD47 multimer comprises a CD47 polypeptide monomer that includes a fusion polypeptide. In some embodiments, the fusion polypeptide includes a multimerization domain. In some embodiments, the multimerization domain comprises an Fc monomer, a c-Jun leucine zipper domain, or a c-Fos leucine zipper domain. In some embodiments, the Fc monomer is a mouse Fc monomer. In some embodiments, the mouse Fc monomer comprises the amino acid sequence set forth in any one of SEQ ID NOs: 81-83. In some embodiments, the fusion polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 84-86. In some embodiments, the CD47 multimer comprises (eg, further comprises) a CD47 polypeptide monomer that includes an epitope tag or ligand. In some embodiments, the epitope tag comprises any one of SEQ ID NOs: 7-32 and 126, or the ligand comprises biotin. In some embodiments, CD47 multimers include soluble CD47 polypeptide monomers.
[0009] In some embodiments, a CD47 multimer comprises at least two CD47 polypeptide monomers linked via a peptide bond. In some embodiments, at least two CD47 polypeptide monomers are linked via a linker peptide. In some embodiments, the linker peptide comprises any one of SEQ ID NOs: 85-109, 127-130, 140, and 141. In some embodiments, the linker peptide includes one or more spacers. In some embodiments, the spacer comprises GS, GGS, or any one of SEQ ID NOs: 52-70. In some embodiments, a CD47 multimer comprises at least two CD47 polypeptide monomers bound to a solid support. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, each of the at least two CD47 polypeptide monomers comprises an epitope tag or a ligand, and a capture agent that specifically binds to the epitope tag or ligand is immobilized on a solid support. , a CD47 polypeptide monomer is bound to a solid support by specific binding of an epitope tag or ligand by a capture agent. In some embodiments, the ligand is biotin and the capture agent is streptavidin. In some embodiments, at least one of the at least two CD47 polypeptide monomers comprises SEQ ID NO: 6. In some embodiments, the CD47 multimer comprises streptavidin or avidin bound to 2, 3, or 4 biotinylated CD47 polypeptide monomers. In some embodiments, at least one of the two, three, or four biotinylated CD47 polypeptide monomers comprises SEQ ID NO:6. In some embodiments, the CD47 multimer is a homomultimer. In some embodiments, the CD47 multimer is a heteromultimer.
[0010] In some embodiments, a method of reducing drug interference in a serological assay using reagent red blood cells (RBCs), reagent platelets, or a combination thereof is provided, the method comprising: (a) reagents specific for human CD47; and (b) adding a SIRP multimer that binds to the reagent red blood cells (RBCs), reagent platelets, or combinations thereof of step (a); performing a serological assay on a plasma sample using an antibody Fc region, wherein the plasma sample is from a subject undergoing treatment with a drug, and the drug comprises: ) a portion that binds human CD47, the SIRP multimer comprising at least two SIRP polypeptide monomers. In some embodiments, a method of reducing drug interference in a serological assay using reagent red blood cells (RBCs), reagent platelets, or a combination thereof is provided, the method comprising: (a) reagents specific for human CD47; adding a SIRP multimer that binds to a plasma sample from a subject undergoing treatment with the drug; and, after step (a), using reagent red blood cells (RBCs), reagent platelets, or a combination thereof. performing a serological assay of the plasma sample, wherein the drug comprises (i) an antibody Fc region and (ii) a moiety that binds human CD47, and the SIRP multimer comprises at least two SIRP polypeptides. Contains monomers. In some embodiments, a method of reducing drug interference in a serological assay of a blood sample containing reagent red blood cells (RBCs), reagent platelets, or a combination thereof is provided, the method comprising: (a) human CD47 adding a SIRP multimer that specifically binds to a blood sample from a subject undergoing treatment with the drug; and (b) performing a serological assay of the blood sample after step (a). wherein the drug comprises (i) an antibody Fc region and (ii) a portion that binds human CD47, and the SIRP multimer comprises at least two SIRP polypeptide monomers.
[0011] In some embodiments, the SIRP multimer comprises 2-100 SIRP polypeptide monomers. In some embodiments, the SIRP multimer comprises a SIRP polypeptide monomer that includes wild type SIRPα or a fragment thereof capable of binding human CD47. In some embodiments, the SIRP multimer is wild-type human SIRPα, wild-type mouse SIRPα, wild-type rat SIRPα, wild-type rhesus SIRPα, wild-type cynomolgus monkey SIRPα, or any of the foregoing, capable of binding human CD47. or a SIRP polypeptide monomer containing one fragment. In some embodiments, the SIRP multimer has one or more amino acid substitutions, insertions, deletions, N-terminal extensions, or C-terminal extensions compared to wild-type SIRPα or a fragment thereof capable of binding CD47. SIRP polypeptide monomers, including SIRPα variants, including SIRPα variants. In some embodiments, the SIRP multimer comprises a SIRP polypeptide monomer that includes wild type SIRPγ or a fragment thereof capable of binding human CD47. In some embodiments, the SIRP multimer is wild-type human SIRPγ, wild-type mouse SIRPγ, wild-type rat SIRPγ, wild-type rhesus SIRPγ, wild-type cynomolgus monkey SIRPγ, or any of the above, capable of binding human CD47. or a SIRP polypeptide monomer containing one fragment. In some embodiments, the SIRP multimer has one or more amino acid substitutions, insertions, deletions, N-terminal extensions, or C-terminal extensions compared to wild-type SIRPγ or a fragment thereof capable of binding CD47. SIRP polypeptide monomers, including SIRPγ variants, including SIRPγ variants. In some embodiments, the SIRP multimer comprises a SIRPβ variant that includes one or more amino acid substitutions, insertions, deletions, N-terminal extensions, or C-terminal extensions as compared to wild-type SIRPβ or a fragment thereof. The SIRP beta variant or fragment thereof, comprising a SIRP polypeptide monomer, is capable of binding to CD47. In some embodiments, the SIRP multimer comprises a SIRP polypeptide monomer comprising an amino acid sequence of any one of SEQ ID NOs: 33-45. In some embodiments, a SIRP multimer comprises a SIRP polypeptide monomer that includes a fusion polypeptide. In some embodiments, the fusion polypeptide includes a multimerization domain. In some embodiments, the multimerization domain comprises an Fc monomer, a c-Jun leucine zipper domain, or a c-Fos leucine zipper domain. In some embodiments, the Fc monomer is a mouse Fc monomer. In some embodiments, the mouse Fc monomer comprises the amino acid sequence set forth in any one of SEQ ID NOs: 81-83. In some embodiments, the fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 110. In some embodiments, a SIRP multimer comprises a SIRP polypeptide monomer that includes an epitope tag or ligand. In some embodiments, the epitope tag comprises any one of SEQ ID NOs: 7-32 and 126, or the ligand comprises biotin. In some embodiments, SIRP multimers include soluble SIRP polypeptide monomers.
[0012] In some embodiments, a SIRP multimer comprises at least two SIRP polypeptide monomers linked via a peptide bond. In some embodiments, a SIRP multimer comprises at least two SIRP polypeptide monomers connected via a linker peptide. In some embodiments, the linker peptide comprises any one of SEQ ID NOs: 85-109, 127-130, 140, and 141. In some embodiments, the linker peptide includes one or more spacers. In some embodiments, the spacer comprises GS, GGS, or any one of SEQ ID NOs: 52-70. In some embodiments, a SIRP multimer comprises at least two SIRP polypeptide monomers attached to a solid support. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, each of the at least two SIRP polypeptide monomers includes an epitope tag or a ligand, and a capture agent that specifically binds to the epitope tag or ligand is immobilized on a solid support. , SIRP polypeptide monomers are bound to a solid support by specific binding of an epitope tag or ligand by a capture agent. In some embodiments, the ligand is biotin and the capture agent is streptavidin. In some embodiments, at least one of the at least two SIRP polypeptide monomers comprises SEQ ID NO: 111. In some embodiments, the SIRP multimer comprises streptavidin or avidin attached to two, three, or four biotinylated SIRP polypeptide monomers. In some embodiments, at least one of the two, three, or four biotinylated SIRP polypeptide monomers comprises SEQ ID NO: 111. In some embodiments, the SIRP multimer is a homomultimer. In some embodiments, the SIRP multimer is a heteromultimer.
[0013] In some embodiments, a method of reducing drug interference in a serological assay using reagent red blood cells (RBCs) or reagent platelets is provided, the method comprising: (a) binding a drug and the drug binding to the reagent RBCs or platelets; (b) after step (a), adding an anti-SIRP multimer that blocks binding to reagent platelets to a plasma sample from a subject undergoing treatment with the drug; performing a serological assay on a plasma sample using an anti-SIRP multimer, the drug comprising (i) a human antibody Fc region or a variant thereof and (ii) a portion that binds human CD47; comprises one or more anti-SIRP antibodies or drug binding fragments thereof.
[0014] In some embodiments, the anti-SIRP multimer comprises an anti-SIRP antibody or drug-binding fragment thereof. In some embodiments, the anti-SIRP multimer comprises 1-100 anti-SIRP antibodies or drug-binding fragments thereof. In some embodiments, the anti-SIRP multimer is an anti-SIRP antibody or drug conjugate thereof that binds to wild-type SIRPα, SIRPα variant, SIRPβ variant, wild-type SIRPγ, SIRPγ variant, or any two or more of the above. Contains fragments. In some embodiments, the anti-SIRP multimer comprises an anti-SIRP antibody or drug-binding fragment thereof comprising: (a) a heavy chain variable domain (V H ) and the light chain variable domain (V L ); (b) heavy chain variable domain (V H ) and the light chain variable domain (V L ); (c) heavy chain variable domain (V H ) and the light chain variable domain (V L ); (d) heavy chain variable domain (V H ) and the light chain variable domain (V L ); (e) heavy chain variable domain (V H ) and the light chain variable domain (V L ); and / or (f) a heavy chain variable domain (V H ) and the light chain variable domain (V L). In some embodiments, the anti-SIRP multimer comprises a full-length anti-SIRP antibody. In some embodiments, the anti-SIRP antibody comprises a mouse Fc domain. In some embodiments, the mouse Fc domain comprises the amino acid sequence set forth in any one of SEQ ID NOs: 81-83. In some embodiments, the anti-SIRP antibody comprises: (a) a heavy chain comprising SEQ ID NO: 117 and a light chain comprising SEQ ID NO: 118; (b) a heavy chain comprising SEQ ID NO: 119 and a light chain comprising SEQ ID NO: 118. (c) a heavy chain comprising SEQ ID NO: 120 and a light chain comprising SEQ ID NO: 121; or (d) a heavy chain comprising SEQ ID NO: 122 and a light chain comprising SEQ ID NO: 121. In some embodiments, the drug-binding fragment of the anti-SIRP antibody is Fab, Fab', F(ab') 2 , Fab'-SH, Fv, diabody, one-arm antibody, scFv, scFv-Fc, single domain antibody, or single heavy chain antibody. In some embodiments, the drug binding fragment comprises F(ab')2, and F(ab')2 comprises SEQ ID NOs: 131 and 132. In some embodiments, the anti-SIRP antibody or drug-binding fragment thereof includes an epitope tag or ligand. In some embodiments, the epitope tag comprises any one of SEQ ID NOs: 7-32 and 126, or the ligand comprises biotin. In some embodiments, the epitope tag comprises HHHHHHGLNDIFEAQKIEWHE (SEQ ID NO: 135) or GSGSHHHHHGLNDIFEAQKIEWHE (SEQ ID NO: 126).
[0015] In some embodiments, an anti-SIRP multimer comprises one or more anti-SIRP antibodies or drug-binding fragments thereof bound to a solid support. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, the one or more anti-SIRP antibodies or drug-binding fragments thereof include an epitope tag or a ligand, and a capture agent that specifically binds to the epitope tag or ligand is immobilized on a solid support. In this case, an anti-SIRP antibody or drug-binding fragment thereof is bound to a solid support by specific binding of an epitope tag or ligand by a capture agent. In some embodiments, the ligand is biotin and the capture agent is streptavidin. In some embodiments, the anti-SIRP multimer comprises streptavidin or avidin coupled to two, three, or four biotinylated anti-SIRP antibodies or fragments thereof. In some embodiments, the anti-SIRP multimer comprises streptavidin or avidin linked to 2, 3, or 4 biotinylated F(ab')2 fragments; two or more of which include SEQ ID NOs: 131 and 132. In some embodiments, the anti-SIRP multimer is a homomultimer. In some embodiments, the anti-SIRP multimer is a heteromultimer.
[0016] In some embodiments of any of the methods herein, the drug comprises an anti-CD47 antibody. In some embodiments, the portion of the drug that binds human CD47 comprises a wild-type SIRPα, a SIRPα variant, or a fragment of a wild-type SIRPα or a SIRPα variant. In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPα variant, and the SIRPα variant comprises one or more amino acid substitution(s), insertion(s), as compared to wild-type SIRPα. ), deletion(s), N-terminal extension(s), and / or C-terminal extension(s). In some embodiments, the portion of the drug that binds human CD47 comprises a fragment of a SIRPα variant, and the fragment comprises an extracellular domain of a SIRPα variant. In some embodiments, the portion of the drug that binds human CD47 comprises wild-type SIRPγ, a SIRPγ variant, or a fragment of wild-type SIRPγ or SIRPγ variant. In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPγ variant, and the SIRPγ variant comprises one or more amino acid substitution(s), insertion(s) as compared to wild-type SIRPγ. ), deletion(s), N-terminal extension(s), C-terminal extension(s), or a combination of any of the above. In some embodiments, the portion of the drug that binds human CD47 comprises a fragment of a SIRPγ variant, and the fragment comprises an extracellular domain of a SIRPγ variant. In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPβ variant or a fragment of a SIRPβ variant. In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPβ variant, and the SIRPβ variant comprises one or more amino acid substitution(s), insertion(s), as compared to wild-type SIRPβ. ), deletion(s), N-terminal extension(s), C-terminal extension(s), or a combination of any of the above. In some embodiments, the portion of the drug that binds human CD47 comprises a fragment of a SIRPβ variant, and the fragment comprises an extracellular domain of a SIRPβ variant. In some embodiments, the antibody Fc region of the drug is a human IgG Fc region or a variant thereof. In some embodiments, the human IgG Fc region is an IgG1, IgG2, or IgG4 Fc region, or a variant of an IgG1, IgG2, or IgG4 Fc region.
[0017] In some embodiments of any of the methods herein, the serological assay is an ABO / Rh typing assay. In some embodiments, the serological assay is an immediate spin (IS) assay. In some embodiments, the serological assay is a direct antiglobulin (DAT) assay that uses multispecific reagents to detect IgG and complement C3. In some embodiments, the serological assay is a direct antiglobulin (DAT) assay that uses a monospecific reagent to detect complement C3. In some embodiments, the serological assay is a PEG-enhanced serological assay. In some embodiments, the serological assay is an eluate test performed after the DAT assay. In some embodiments, the serological assay is a test tube assay or solid phase red blood cell assay (SPRCA).
[0018] Provided herein are CD47 multimers that include at least two CD47 polypeptide monomers. In some embodiments, the CD47 multimer comprises 2-100 CD47 polypeptide monomers. In some embodiments, the CD47 multimer comprises a CD47 polypeptide monomer that includes wild-type CD47 or a fragment thereof that is capable of binding a drug. In some embodiments, the CD47 multimer is wild-type human CD47, wild-type mouse CD47, wild-type rat CD47, wild-type rhesus CD47, wild-type cynomolgus monkey CD47, or any of the above, which is capable of binding the drug. Contains a CD47 polypeptide monomer containing one fragment. In some embodiments, the CD47 multimer comprises a CD47 polypeptide monomer comprising the amino acid sequence of SEQ ID NO:1. In some embodiments, the CD47 multimer has one or more amino acid substitutions, insertions, deletions, N-terminal extensions, or C-terminal extensions compared to wild-type CD47 or a fragment thereof that is capable of binding the drug. CD47 polypeptide monomers, including CD47 variants, including CD47 variants. In some embodiments, the CD47 multimer comprises a CD47 polypeptide monomer comprising the amino acid sequence set forth in any one of SEQ ID NOs: 2-6. In some embodiments, a CD47 multimer comprises a CD47 polypeptide monomer that includes a fusion polypeptide. In some embodiments, the fusion polypeptide includes a multimerization domain. In some embodiments, the multimerization domain comprises an Fc monomer, a c-Jun leucine zipper domain, or a c-Fos leucine zipper domain. In some embodiments, the Fc monomer is a mouse Fc monomer. In some embodiments, the mouse Fc monomer comprises the amino acid sequence set forth in any one of SEQ ID NOs: 81-83. In some embodiments, the fusion polypeptide CD47 polypeptide monomer comprises the amino acid sequence set forth in any one of SEQ ID NOs: 84-86. In some embodiments, a CD47 multimer comprises a CD47 polypeptide monomer that includes an epitope tag or ligand. In some embodiments, the epitope tag comprises any one of SEQ ID NOs: 7-32 and 126, or the ligand comprises biotin. In some embodiments, CD47 multimers include soluble CD47 polypeptide monomers.
[0019] In some embodiments, a CD47 multimer comprises at least two CD47 polypeptide monomers linked via a peptide bond. In some embodiments, a CD47 multimer comprises at least two CD47 polypeptide monomers connected via a linker peptide. In some embodiments, the linker peptide comprises any one of SEQ ID NOs: 85-109, 127-130, 140, and 141. In some embodiments, the linker peptide includes one or more spacers. In some embodiments, the spacer comprises GS, GGS, or any one of SEQ ID NOs: 52-70. In some embodiments, the CD47 multimer comprises at least two CD47 multimers comprising multiple CD47 polypeptide monomers bound to a solid support. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, each of the at least two CD47 polypeptide monomers includes an epitope tag or a ligand, and a capture agent that specifically binds to the epitope tag or ligand is immobilized on a solid support. , a CD47 polypeptide monomer is bound to a solid support by specific binding of an epitope tag or ligand by a capture agent. In some embodiments, the ligand is biotin and the capture agent is streptavidin. In some embodiments, at least one of the at least two CD47 polypeptide monomers comprises SEQ ID NO: 6. In some embodiments, the CD47 multimer comprises streptavidin or avidin bound to 2, 3, or 4 biotinylated CD47 polypeptide monomers. In some embodiments, at least one of the two, three, or four biotinylated CD47 polypeptide monomers comprises SEQ ID NO:6. In some embodiments, the CD47 multimer is a homomultimer. In some embodiments, the CD47 multimer is a heteromultimer.
[0020] In some embodiments, SIRP multimers are provided that include at least two SIRP polypeptide monomers. In some embodiments, the SIRP multimer comprises 2-100 SIRP polypeptide monomers. In some embodiments, the SIRP multimer comprises a SIRP polypeptide monomer that includes wild type SIRPα or a fragment thereof capable of binding human CD47. In some embodiments, the SIRP multimer is wild-type human SIRPα, wild-type mouse SIRPα, wild-type rat SIRPα, wild-type rhesus SIRPα, wild-type cynomolgus monkey SIRPα, or any of the foregoing, capable of binding human CD47. or a SIRP polypeptide monomer containing one fragment. In some embodiments, the SIRP multimer has one or more amino acid substitutions, insertions, deletions, N-terminal extensions, or C-terminal extensions compared to wild-type SIRPα or a fragment thereof capable of binding CD47. SIRP polypeptide monomers, including SIRPα variants, including SIRPα variants. In some embodiments, the SIRP multimer comprises a SIRP polypeptide monomer that includes wild type SIRPγ or a fragment thereof capable of binding human CD47. In some embodiments, the SIRP multimer is wild-type human SIRPγ, wild-type mouse SIRPγ, wild-type rat SIRPγ, wild-type rhesus SIRPγ, wild-type cynomolgus monkey SIRPγ, or any of the above, capable of binding human CD47. or a SIRP polypeptide monomer containing one fragment. In some embodiments, the SIRP multimer has one or more amino acid substitutions, insertions, deletions, N-terminal extensions, or C-terminal extensions compared to wild-type SIRPγ or a fragment thereof capable of binding CD47. SIRP polypeptide monomers, including SIRPγ variants, including SIRPγ variants. In some embodiments, the SIRP multimer comprises a SIRPβ variant that includes one or more amino acid substitutions, insertions, deletions, N-terminal extensions, or C-terminal extensions as compared to wild-type SIRPβ or a fragment thereof. The SIRP beta variant or fragment thereof, comprising a SIRP polypeptide monomer, is capable of binding to CD47. In some embodiments, the SIRP multimer comprises a SIRP polypeptide monomer comprising an amino acid sequence of any one of SEQ ID NOs: 33-45. In some embodiments, a SIRP multimer comprises a SIRP polypeptide monomer that includes a fusion polypeptide. In some embodiments, the fusion polypeptide includes a multimerization domain. In some embodiments, the multimerization domain comprises an Fc monomer, a c-Jun leucine zipper domain, or a c-Fos leucine zipper domain. In some embodiments, the Fc monomer is a mouse Fc monomer. In some embodiments, the mouse Fc monomer comprises the amino acid sequence set forth in any one of SEQ ID NOs: 81-83. In some embodiments, the fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 110. In some embodiments, a SIRP multimer comprises a SIRP polypeptide monomer that includes an epitope tag or ligand. In some embodiments, the epitope tag comprises any one of SEQ ID NOs: 7-32 and 126, or the ligand comprises biotin. In some embodiments, SIRP multimers include soluble SIRP polypeptide monomers.
[0021] In some embodiments, a SIRP multimer comprises at least two SIRP polypeptide monomers linked via a peptide bond. In some embodiments, a SIRP multimer comprises at least two SIRP polypeptide monomers connected via a linker peptide. In some embodiments, the linker peptide comprises any one of SEQ ID NOs: 85-109, 127-130, 140, and 141. In some embodiments, the linker peptide includes one or more spacers. In some embodiments, the spacer comprises GS, GGS, or any one of SEQ ID NOs: 52-70. In some embodiments, a SIRP multimer comprises at least two SIRP polypeptide monomers attached to a solid support. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, each of the at least two SIRP polypeptide monomers includes an epitope tag or a ligand, and a capture agent that specifically binds to the epitope tag or ligand is immobilized on a solid support. , SIRP polypeptide monomers are bound to a solid support by specific binding of an epitope tag or ligand by a capture agent. In some embodiments, the ligand is biotin and the capture agent is streptavidin. In some embodiments, at least one of the at least two SIRP polypeptide monomers comprises SEQ ID NO: 111. In some embodiments, the SIRP multimer comprises streptavidin or avidin attached to two, three, or four biotinylated SIRP polypeptide monomers. In some embodiments, at least one of the two, three, or four biotinylated SIRP polypeptide monomers comprises SEQ ID NO: 111. In some embodiments, the SIRP multimer is a homomultimer. In some embodiments, the SIRP multimer is a heteromultimer.
[0022] In some embodiments, provided herein are anti-SIRP multimers that include one or more anti-SIRP antibodies or drug-binding fragments thereof. In some embodiments, the anti-SIRP multimer comprises 1-100 anti-SIRP antibodies or drug-binding fragments thereof. In some embodiments, the anti-SIRP multimer is an anti-SIRP antibody or drug conjugate thereof that binds to wild-type SIRPα, SIRPα variant, SIRPβ variant, wild-type SIRPγ, SIRPγ variant, or any two or more of the above. Contains fragments. In some embodiments, the anti-SIRP multimer comprises an anti-SIRP antibody or drug-binding fragment thereof comprising: (a) a heavy chain variable domain (V H ) and the light chain variable domain (V L ); (b) heavy chain variable domain (V H ) and the light chain variable domain (V L ); (c) heavy chain variable domain (V H ) and the light chain variable domain (V L ); (d) heavy chain variable domain (V H ) and the light chain variable domain (V L ); (e) heavy chain variable domain (V H ) and the light chain variable domain (V L ); and / or (f) a heavy chain variable domain (V H ) and the light chain variable domain (V L ). In some embodiments, the anti-SIRP multimer comprises a full-length anti-SIRP antibody. In some embodiments, the anti-SIRP antibody comprises a mouse Fc domain. In some embodiments, the mouse Fc domain comprises the amino acid sequence set forth in any one of SEQ ID NOs: 81-83. In some embodiments, the anti-SIRP antibody comprises: (a) a heavy chain comprising SEQ ID NO: 117 and a light chain comprising SEQ ID NO: 118; (b) a heavy chain comprising SEQ ID NO: 119 and a light chain comprising SEQ ID NO: 118; (c) a heavy chain comprising SEQ ID NO: 120 and a light chain comprising SEQ ID NO: 121; or (d) a heavy chain comprising SEQ ID NO: 122 and a light chain comprising SEQ ID NO: 121. In some embodiments, the drug-binding fragment of the anti-SIRP antibody is Fab, Fab', F(ab') 2, Fab'-SH, Fv, diabody, one-arm antibody, scFv, scFv-Fc, single domain antibody, or single heavy chain antibody. In some embodiments, the drug binding fragment comprises F(ab')2, and F(ab')2 comprises SEQ ID NOs: 131 and 132. In some embodiments, the anti-SIRP antibody or drug-binding fragment thereof includes an epitope tag or ligand. In some embodiments, the epitope tag comprises any one of SEQ ID NOs: 7-32 and 126, or the ligand comprises biotin. In some embodiments, the epitope tag comprises HHHHHHGLNDIFEAQKIEWHE (SEQ ID NO: 135) or GSGSHHHHHGLNDIFEAQKIEWHE (SEQ ID NO: 126).
[0023] In some embodiments, an anti-SIRP multimer comprises one or more anti-SIRP antibodies or drug-binding fragments thereof bound to a solid support. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, each of the one or more anti-SIRP antibodies or drug-binding fragments thereof includes an epitope tag or a ligand, and a capture agent that specifically binds to the epitope tag or ligand is immobilized on a solid support. The anti-SIRP antibody or drug-binding fragment thereof is bound to a solid support by specific binding of an epitope tag or ligand by a capture agent. In some embodiments, the ligand is biotin and the capture agent is streptavidin. In some embodiments, the anti-SIRP multimer comprises streptavidin or avidin coupled to two, three, or four biotinylated anti-SIRP antibodies or fragments thereof. In some embodiments, the anti-SIRP multimer comprises streptavidin or avidin linked to 2, 3, or 4 biotinylated F(ab')2 fragments; two or more of which include SEQ ID NOs: 131 and 132. In some embodiments, the anti-SIRP multimer is a homomultimer. In some embodiments, the anti-SIRP multimer is a heteromultimer.
[0024] All references cited herein, including patent applications, patent publications, and UniProtKB / Swiss-Prot accession numbers, are cited herein as if each individual reference were specifically and individually incorporated by reference. Incorporated herein by reference in its entirety as if indicated. [Brief explanation of the drawing]
[0025] [Figure 1A] To detect the presence of antibodies in a plasma sample that bind to RBC surface antigens, a plasma sample obtained from a subject is tested for reagent red blood cells (i.e., known to express a particular cell surface antigen, or group of cell surface antigens). Figure 2 shows a serological assay in which red blood cells ("RBC")) are mixed. Alternatively, such serological assays may be performed using reagent platelets (i.e., platelets known to express a particular cell surface antigen or group of cell surface antigens) instead of reagent RBCs. can.
[0026] [Figure 1B] Figure 1A shows how the presence of a drug comprising (i) an antibody Fc region and (ii) a moiety that binds human CD47 in a plasma sample interferes with the assay of Figure 1A.
[0027] [Figure 1C] To detect the presence of antigens on RBCs and / or platelets of a subject, reagent plasma / antiserum (i.e., may contain antibodies to specific RBC surface antigen(s) or platelet surface antigen(s)) Figure 2 depicts a serological assay in which a known plasma or antiserum) and a blood sample obtained from a subject are mixed.
[0028] [Figure 1D] Figure 1C shows how the presence of a drug comprising (i) an antibody Fc region and (ii) a moiety that binds human CD47 in a blood sample interferes with the assay of Figure 1C.
[0029]
Figure 2
[0030] [Figure 3A] A method of reducing interference in a serological assay is shown comprising adding a SIRP multimer that binds CD47 to reagent RBCs or reagent platelets. In summary, SIRP multimers bind to CD47 on the surface of reagent RBCs or reagent platelets. Binding of reagent RBCs (or reagent platelets) by SIRP multimers blocks drug binding to reagent RBCs (or reagent platelets).
[0031] [Figure 3B] A method of reducing interference in a serological assay is shown comprising adding a SIRP multimer that binds CD47 to plasma from a subject undergoing treatment with a drug. In summary, SIRP multimers compete with drugs for binding to CD47 expressed on the surface of reagent RBCs or reagent platelets, minimizing the amount of drug-binding reagent RBCs or platelets in the assay (or (remove drug-binding reagent RBCs and / or drug-binding reagent platelets in the assay).
[0032] [Figure 3C] A method of reducing interference in a serological assay is shown comprising adding a SIRP multimer that binds CD47 to a blood sample from a subject undergoing treatment with a drug. In summary, SIRP multimers compete with drugs for binding to CD47 expressed on the surface of RBCs and / or platelets of interest, minimizing the amount of drug-bound RBCs and / or platelets in the assay. (or remove).
[0033] [Figure 3D] A method of reducing interference in a serological assay is shown comprising adding a SIRP multimer that binds a drug to a plasma sample from a subject undergoing treatment with a drug. In summary, SIRP multimers bind drugs in plasma samples, so that little or no drug is available to bind to CD47 on the surface of reagent RBCs or reagent platelets.
[0034] [Figure 4] Results of an experiment conducted to compare the extent to which CD47 polypeptide monomer, CD47 multimer B, anti-SIRP multimer C, and anti-SIRP multimer D inhibit interference by drug A in an IAT test tube assay. I will provide a.
[0035] [Figure 5] Further experiments were conducted to compare the extent to which CD47 polypeptide monomer, CD47 multimer B, anti-SIRP multimer C, and anti-SIRP multimer D inhibit interference by drug A in the IAT test tube assay. provide results.
[0036] [Figure 6] Further experiments were conducted to compare the extent to which CD47 polypeptide monomer, CD47 multimer B, anti-SIRP multimer C, and anti-SIRP multimer D inhibit interference by drug A in the IAT test tube assay. provide results.
[0037] [Figure 7] A solid-phase red blood cell adhesion assay (SPRCA) was conducted to compare the extent to which CD47 polypeptide monomer, CD47 multimer B, anti-SIRP multimer C, and anti-SIRP multimer D inhibit interference by drug A. We provide the results of the experiments.
[0038] [Figure 8] We provide the results of experiments performed to test whether anti-SIRP multimer C or anti-SIRP multimer F inhibits interference by drug A in the solid phase red blood cell adhesion assay (SPRCA). [Details for carrying out the invention]
[0039] I. How to reduce interference in pre-transfusion serological assays CD47 is a transmembrane protein that interacts with several molecules on immune cells, including thrombospondin 1 (TSP-1) and signal regulatory protein alpha (SIRPα). Upon binding to CD47, SIRPα initiates a signaling cascade that inhibits phagocytosis and prevents phagocytic removal of healthy cells by the immune system. However, many cancers overexpress CD47 and evade clearance by phagocytes. Therefore, drugs that target CD47 (eg, anti-CD47 antibodies and fusion proteins comprising an antibody Fc region and a portion that binds CD47) are of significant therapeutic interest. CD47 is also expressed on the surface of human red blood cells (RBCs) and platelets. Thus, after administering to a subject a drug that includes (i) an antibody Fc region and (ii) a portion that binds human CD47, the drug is present in the subject's plasma or bound to the subject's RBCs and / or platelets. Drugs can cause interference with routine pre-transfusion serological assays.
[0040] For example, FIG. 1A shows that a plasma sample obtained from a subject contains reagent RBCs or "reference RBCs" (i.e., RBCs known to express a particular cell surface antigen or group of cell surface antigens); Serological assays are shown in which platelets or "reference platelets" (ie, platelets known to express a particular cell surface antigen or group of cell surface antigens) are mixed. This detects the presence in a plasma sample of antibodies that bind to cell surface antigens known to be expressed on reagent RBCs or reagent platelets. Anti-human globulin (AHG) is added after the plasma sample and reagent RBCs (or reagent platelets) are mixed, and if the plasma sample contains antibodies that bind to RBC surface antigens (or platelet surface antigens), reagent RBCs (or reagent platelets) aggregation (eg, aggregation) occurs. However, the presence of a drug containing (i) an antibody Fc region and (ii) a moiety that binds human CD47 in a subject's plasma can interfere with the assay and produce false positive results. As shown in FIG. 1B, after the subject's plasma and reagent RBCs (or reagent platelets) are mixed, the drug can bind to CD47 that is expressed on the surface of the reagent RBCs (or reagent platelets). Addition of AHG to the mixture causes aggregation of reagent RBCs (or reagent platelets).
[0041] Figure 1C shows a serological assay to detect the presence of antigens on a subject's RBCs and / or platelets (i.e., a blood sample from a subject is combined with reagent plasma / antiserum (i.e., known RBC surface antigen(s) or known RBC surface antigen(s) or (mixed with plasma or antiserum) containing antibodies against platelet surface antigen(s). After mixing the reagent plasma / antiserum and the sample from the subject, if the antigen recognized by the antibody in the reagent plasma / antiserum is expressed on the subject's RBCs and / or platelets, the addition of AHG will cause agglutination. occurs. The presence of a drug containing (i) an antibody Fc region and (ii) a moiety that binds human CD47 in a sample containing RBCs and / or platelets of a subject can interfere with the assay and result in false positive results. As shown in Figure 1D, after AHG is added to the mixture containing the subject's blood sample and reagent plasma / antiserum, the drug binding to CD47 on the subject's RBCs or platelets does not cause aggregation. Probably.
[0042] The methods described below reduce (in some embodiments eliminate) drug-induced interference, ie, as shown in FIGS. 1B and 1D.
[0043] II. Method of using CD47 multimers conjugated to drugs to reduce interference in pre-transfusion serological assays In some embodiments, the method comprises: (a) producing a CD47 multimer that binds a drug (i.e., a moiety of the drug that includes a moiety that binds human CD47) in a plasma sample from a subject undergoing treatment with the drug; and (b) after step (a), reagent RBCs (i.e. RBCs known to express a particular cell surface antigen or group of cell surface antigens) and / or reagent platelets (i.e. performing a serological assay of a plasma sample using platelets (platelets known to express a particular cell surface antigen or group of cell surface antigens), the drug comprising: (i) an antibody Fc region; (ii) Contains a portion that binds to human CD47. Such an embodiment is generally shown in FIG. As shown in Figure 2, the CD47 multimer binds to the drug (e.g., the portion of the drug that binds to human CD47) in the subject's plasma sample, and the drug binds to reagent RBCs and / or reagent platelets. to block the There is little or no free drug binding to CD47 on the surface of reagent RBCs and / or reagent platelets. Interferences resulting from drug binding to reagent RBCs and / or reagent platelets (shown in Figure 1B) are minimized (or, in some embodiments, eliminated), thereby reducing serological False positive results in assays are prevented. In some embodiments, about 1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x compared to the amount of drug in plasma. times, 6.5 times, 7 times, 7.5 times, 8 times, 8.5 times, 9 times, 9.5 times, 10 times, 10.5 times, 11 times, 11.5 times, 12 times, 12.5 times, 13 times, 13.5 times, 14 times, CD47 multimer is added to the plasma sample to obtain a 14.5-fold or 15-fold molar excess of either one of the anti-SIRP multimers. In some embodiments, CD47 multimers are also added to reagent RBCs and / or reagent platelets before the serological assay is performed. In some embodiments, CD47 multimers are added to reagent RBCs and / or reagent platelets (eg, reagent RBCs and / or reagent platelets only) before the serological assay is performed.
[0044] In some embodiments, the method is performed in solution, eg, where the CD47 multimer is soluble. In some embodiments, the CD47 multimer is immobilized on a solid phase before the method is performed via adsorption to a matrix or surface, covalent binding, or non-covalent binding. In some embodiments, the CD47 multimer can be conjugated to a drug after immobilization to a solid phase or solid support. The solid phase or solid support used for immobilization is essentially water-insoluble and can be any inert support, surface, or carrier useful in immunoassays, including, for example, surfaces, particles, including supports in the form of porous matrices, cellulose polymer sponges (ImmunoCAP®, Phadia), and the like. Examples of commonly used supports include small sheets, Sephadex, polyvinyl chloride, plastic beads, gold beads, microparticles, assay plates, or test tubes made from polyethylene, polypropylene, polystyrene, and the like. In some embodiments, CD47 multimers are coated onto microtiter plates, such as multiwell microtiter plates, which can be used to analyze multiple samples simultaneously.
[0045] In some embodiments, the portion of the drug that binds human CD47 comprises a wild-type SIRPα, a SIRPα variant, or a CD47-binding fragment of a wild-type SIRPα or a SIRPα variant. In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPα variant (or a CD47-binding fragment thereof), and the SIRPα variant (or a CD47-binding fragment thereof) is a wild-type SIRPα (or a CD47-binding fragment thereof) contains one or more amino acid substitution(s), insertion(s), deletion(s), N-terminal extension(s), and / or C-terminal extension(s) as compared to . In some embodiments, the portion of the drug that binds human CD47 comprises a fragment of a SIRPα variant, and the fragment comprises an extracellular domain of a SIRPα variant. In some embodiments, the CD47 multimer is capable of binding a wild-type SIRPα, a SIRPα variant, or a fragment of a wild-type SIRPα or a SIRPα variant.
[0046] In some embodiments, the portion of the drug that binds human CD47 comprises a wild-type SIRPγ, a SIRPγ variant, or a CD47-binding fragment of a wild-type SIRPγ or a SIRPγ variant. In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPγ variant, and the SIRPγ variant comprises one or more amino acid substitution(s), insertion(s), as compared to wild-type SIRPγ. ), deletion(s), N-terminal extension(s), C-terminal extension(s), or a combination of any of the above. In some embodiments, the portion of the drug that binds human CD47 comprises a CD47 binding fragment of a SIRPγ variant, and the fragment comprises an extracellular domain of a SIRPγ variant. In some embodiments, the CD47 multimer is capable of binding wild-type SIRPγ, a SIRPγ variant, or a fragment of wild-type SIRPγ or SIRPγ variant.
[0047] In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPβ variant capable of binding CD47 (eg, human CD47), or a fragment of a SIRPβ variant capable of binding CD47 (eg, human CD47). In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPβ variant, and the SIRPβ variant comprises one or more amino acid substitution(s), insertion(s), as compared to wild-type SIRPβ. ), deletion(s), N-terminal extension(s), C-terminal extension(s), or a combination of any of the above. In some embodiments, the portion of the drug that binds human CD47 comprises a fragment of a SIRPβ variant, the fragment comprising the extracellular domain of the SIRPβ variant and capable of binding CD47 (eg, human CD47). In some embodiments, the CD47 multimer is capable of binding a SIRPβ variant, or a CD47 binding fragment of a SIRPβ variant.
[0048] In some embodiments, the drug comprises an anti-CD47 antibody (or a CD47-binding fragment thereof), and the CD47 multimer is capable of binding the anti-CD47 antibody (or a CD47-binding fragment thereof).
[0049] (a) CD47 multimer containing CD47 polypeptide monomer In some embodiments, a CD47 multimer comprises multiple CD47 polypeptide monomers. In some embodiments, the CD47 multimer is 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or up to 100 CD47 polypeptide monomers, including any range between these values. In some embodiments, the CD47 polypeptide monomer is a wild-type CD47 (“WTCD47-ECD”) capable of binding the drug and blocking the binding of the drug to reagent RBCs and / or reagent platelets. ), or a portion of WT CD47-ECD. In some embodiments, the CD47 polypeptide monomer is a soluble polypeptide that does not include the transmembrane domain of CD47 or any portion thereof. In some embodiments, a CD47 polypeptide monomer comprises a fusion polypeptide, eg, a fusion polypeptide comprising CD47 (or a fragment thereof). In some embodiments, the fusion polypeptide comprises a CD47 polypeptide monomer (or a fragment thereof) and, for example, an antibody Fc domain, such as a mouse Fc domain. As discussed in more detail elsewhere herein, in some embodiments, the fusion polypeptide comprises a CD47 polypeptide monomer and a multimerization domain. In some embodiments, the CD47 polypeptide monomer is human CD47, mouse CD47, rat CD47 capable of binding to a drug and blocking the binding of the drug to reagent RBCs and / or reagent platelets. , including rhesus CD47, cynomolgus CD47, or CD47 of any origin. In some embodiments, the CD47 polypeptide monomer comprises human CD47, mouse CD47, rat CD47, rhesus CD47, cynomolgus CD47, or a fragment of CD47 of any origin. However, the fragment can bind to the drug and block the drug from binding to reagent RBCs and / or reagent platelets. In some embodiments, the CD47 polypeptide monomer is a variant of wild-type CD47 (or a fragment thereof, e.g., a variant of WT CD47-ECD or a variant of CD47 that does not include the transmembrane domain of CD47 or any portion thereof). )including. However, the variant is capable of binding to drugs. In some embodiments, the variant (or fragment thereof) comprises one or more amino acid substitution(s) compared to wild-type CD47 (e.g., wild-type human, rat, mouse, rhesus, or cynomolgus CD47). ), deletion(s), insertion(s), N-terminal addition(s), and / or C-terminal addition(s). In some embodiments, one or more amino acid substitution(s), deletion(s), insertion(s), N-terminal addition(s) present in the variant (i.e., "CD47 variant") ), and / or C-terminal addition(s) alter the glycosylation pattern of the CD47 variant compared to wild-type CD47 (eg, wild-type human, rat, mouse, rhesus, or cynomolgus CD47). In some embodiments, one or more amino acid substitution(s), deletion(s), insertion(s), N-terminal addition(s), and / or C-terminal addition(s) present in the CD47 variant. The addition(s) increases the affinity of the CD47 variant for the drug compared to wild-type CD47 (eg, wild-type human, rat, mouse, rhesus, or cynomolgus CD47). In some embodiments, the affinity of the drug for CD47 polypeptide monomer is greater than the affinity of the drug for human CD47.
[0050] In some embodiments, the CD47 polypeptide monomer comprises a CD47 variant comprising an amino acid sequence of any one of the following SEQ ID NOs: 1-6: QLLFNKTKSV EFTFSNDTVV IPCFVTNMEA QNTTEVYVKW KFKGRDIYTF DGALNKSTVP TDFSSAKIEV SQLLKGDASL KMDKSDAVSH TGNYTCEVTE LTREGETIIE LKYRVVS (SEQ ID NO: 1) WQLPLLFNKT KSVEFTFGND TVVIPCFVTN MEAQNTTEVY VKWKFKGRDI YTFDGDKNKS TVPTDFSSAK IEVSQLLKGD ASLKMDKSDA VSHTGNYTCE VTELTREGET IIELKYRVVS (SEQ ID NO: 2) WQPPLLFNKT KSVEFTFGND TVVIPCFVTN MEAQNTTEVY VKWKFKGRDI YTFDGQANKS TVPTDFSSAK IEVSQLLKGD ASLKMDKSDA VSHTGNYTCE VTELTREGET IIELKYRVVS (SEQ ID NO: 3) WQPPLLFNKT KSVEFTFCND TVVIPCFVTN MEAQNTTEVY VKWKFKGRDI YTFDGQANKS TVPTDFSSAK IEVSQLLKGD ASLKMDKSDA VSHTGNYTCE VTELTREGET IIELKYRVVS (SEQ ID NO: 4) WQPPLLFNKT KSVEFTCGND TVVIPCFVTN MEAQNTTEVY VKWKFKGRDI YTFDGQANKS TVPTDFSSAK IEVSQLLKGD ASLKMDKSDA VSHTGNYTCE VTELTREGET IIELKYRVVS (SEQ ID NO: 5) QLLFNKTKSV EFTFSNDTVV IPCFVTNMEA QNTTEVYVKW KFKGRDIYTF DGALNKSTVP TDFSSAKIEV SQLLKGDASL KMDKSDAVSH TGNYTCEVTE LTREGETIIE LKYRVVSHHH HHHGLNDIFE AQKIEWHE (SEQ ID NO: 6)
[0051] In some embodiments, the CD47 multimer comprises SEQ ID NO: 6. In some embodiments, about 1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x compared to the amount of drug in plasma. To obtain any one of the following: CD47 multimers in plasma added to a sample (eg, a plasma sample obtained from a subject undergoing treatment with a drug).
[0052] Further details regarding exemplary CD47 polypeptide monomers (e.g., including CD47 variants) that can be multimerized and used in the methods described herein can be found in Ho et al. (2015) “'Velcro' Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein a(SIRPα)Antagonists That Enhance Antibody-Dependent Cellular Phagocytosis.”J Biol Chem.290:12650-12663 and WO2016 / 179399, the contents of which are Incorporated herein by reference.
[0053] In some embodiments, the CD47 polypeptide monomer comprises a fusion polypeptide that includes a multimerization domain. Exemplary multimerization domains include, but are not limited to, Fc monomers such as mouse Fc monomers, c-Jun leucine zipper domains, and c-Fos leucine zipper domains. Each of these multimerization domains is capable of forming dimers. In some embodiments, multimerization includes GVGVP (SEQ ID NO: 71), VPGG (SEQ ID NO: 142), APGVGV (SEQ ID NO: 72), GAGAGS (SEQ ID NO: 73), GPGGG (SEQ ID NO: 74), GPGGX (formula (wherein, ), AKLKLAEAKLELA (SEQ ID NO: 78), PPAKVPEVPEPKKPVPVPEEKVPVPKKPEA (SEQ ID NO: 79), and / or GGFGGMGGGX (wherein X is any amino acid (SEQ ID NO: 80)). See, for example: Tatham et al. (2000) Trends in Biochemical Sciences, 25, 567-571; Sanford and Kumar (2005) Current Opinion in Biotechnology, 16, 416-421; and Casal et al. (2014) Future Trends for Recombinant Protein-Based Polymers: The Case Study of Development and Application of Silk-Elastin-Like Polymers. In Kabasci (Ed.) Bio-Based Plastics: Materials and Applications (pp. 311-32) John Wiley & Sons, Ltd..
[0054] In some embodiments, the CD47 polypeptide monomer comprises a fusion polypeptide comprising any one of SEQ ID NOs: 1-6 and any one of SEQ ID NOs: 81-83. The amino acid sequences of SEQ ID NOs: 81-83 are described below. SEQ ID NO: 81 contains the CH2 and CH3 domains of mouse IgG1. SEQ ID NO: 82 contains the CH2 and CH3 domains of mouse IgG1, the CH3 domain contains the N297A substitution, and the amino acid numbering follows Kabat's EU index. SEQ ID NO: 83 contains the CH2 and CH3 domains of mouse IgG2a. VPRDSGCKPC ICTVPEVSSV FIFPPKPKDV LTITLTPKVT CVVVDISKDD PEVQFSWFVD DVEVHTAQTQ PREEQFNSTF RSVSELPIMH QDWLNGKEFK CRVNSAAFPA PIEKTISKTK GRPKAPQVYT IPPPKEQMAK DKVSLTCMIT DFFPEDITVE WQWNGQPAEN YKNTQPIMDT DGSYFIYSKL NV QKSNWEAG NTFTCSVLHE GLHNHHTEKS LSHSPG (SEQ ID NO: 81) VPRDSGCKPC ICTVPEVSSV FIFPPKPKDV LTITLTPKVT CVVVDISKDD PEVQFSWFVD DVEVHTAQTQ PREEQFASTF RSVSELPIMH QDWLNGKEFK CRVNSAAFPA PIEKTISKTK GRPKAPQVYT IPPPKEQMAK DKVSLTCMIT DFFPEDITVE WQWNGQPAEN YKNTQPIMDT DGSYFIYSKL NV QKSNWEAG NTFTCSVLHE GLHNHHTEKS LSHSPG (SEQ ID NO: 82) EPRGPTIKPC PPCKCPAPNL LGGPSVFIFP PKIKDVLMIS LSPIVTCVVV DVSEDDPDVQ ISWFVNNVEV HTAQTQTHRE DYNSTLRVVS ALPIQHQDWM SGKEFKCKVN NKDLPAPIER TISKPKGSVR APQVYVLPPP EEEMTKKQVT LTCMVTDFMP EDIYVEWTNN GKTELNYKNT EPVLDSDGSY FMYSKLR VEK KNWVERNSYS CSVVHEGLHN HHTTKSFSRT PG (SEQ ID NO: 83)
[0055] In some embodiments, the CD47 polypeptide monomer comprises a fusion polypeptide whose amino acid sequence is set forth in any one of SEQ ID NOs: 84-86 below. QLLFNKTKSV EFTFSNDTVV IPCFVTNMEA QNTTEVYVKW KFKGRDIYTF DGALNKSTVP TDFSSAKIEV SQLLKGDASL KMDKSDAVSH TGNYTCEVTE LTREGETIIE LKYRVVSVPR DSGCKPCICT VPEVSSVFIF PPKPKDVLTI TLTPKVTCVV VDISKDDPEV QFSWFVDDVE VHTAQTQPRE EQFNSTFRSV SELPIMHQDW LNGKEFKCRV NSAAFPAPIE KTISKTKGRP KAPQVYTIPP PKEQMAKDKV SLTCMITDFF PEDITVEWQW NGQPAENYKN TQPIMDTDGS YFIYSKLNVQ KSNWEAGNTF TCSVLHEGLH NHHTEKSLSH SPG (Sequence number 84) QLLFNKTKSV EFTFSNDTVV IPCFVTNMEA QNTTEVYVKW KFKGRDIYTF DGALNKSTVP TDFSSAKIEV SQLLKGDASL KMDKSDAVSH TGNYTCEVTE LTREGETIIE LKYRVVSVPR DSGCKPCICT VPEVSSVFIF PPKPKDVLTI TLTPKVTCVV VDISKDDPEV QFSWFVDDVE VHTAQTQPRE EQFASTFRSV SE LPIMHQDW LNGKEFKCRV NSAAFPAPIE KTISKTKGRP KAPQVYTIPP PKEQMAKDKV SLTCMITDFF PEDITVEWQW NGQPAENYKN TQPIMDTDGS YFIYSKLNVQ KSNWEAGNTF TCSVLHEGLH NHHTEKSLSH SPG (Sequence number 85) QLLFNKTKSV EFTFSNDTVV IPCFVTNMEA QNTTEVYVKW KFKGRDIYTF DGALNKSTVP TDFSSAKIEV SQLLKGDASL KMDKSDAVSH TGNYTCEVTE LTREGETIIE LKYRVVSEPR GPTIKPSPPC KCPAPNLLGG PSVFIFPPKI KDVLMISLSP IVTCVVVDVS EDDPDVQISW FVNNVEVHTA QTQTHREDYN STLRVVSALP IQHQDWMSGK EFKCKVNNKD LPAPIERTIS KPKGSVRAPQ VYVLPPPEEE MTKKQVTLTC MVTDFMPEDI YVEWTNNGKT ELNYKNTEPV LDSDGSYFMY SKLRVEKKNW VERNSYSCSV VHEGLHNHHT TKSFSRTPG (Sequence number 86)
[0056] In some embodiments, the CD47 polypeptide monomer (eg, fusion polypeptide) includes (eg, further includes) an epitope tag. In some embodiments, the epitope tag promotes multimerization of CD47 polypeptide monomers. In some embodiments, the tag facilitates immobilization of CD47 polypeptide monomers to a solid support (eg, beads, glass slides, etc.). Exemplary epitope tags include, for example, HHHHHH (SEQ ID NO: 7), GLNDIFEAQKIEWHE (SEQ ID NO: 8), SRLEEELRRRLTE (SEQ ID NO: 9), KRRWKKNFIAVSAANRFKKISSSGAL (SEQ ID NO: 10), polyglutamate tags, such as EEEEEE (SEQ ID NO: 11). , GAPVPYPDPLEPR (SEQ ID NO: 12), DYKDDDDK (SEQ ID NO: 13), YPYDVPDYA (SEQ ID NO: 14), TKENPRSNQEESYDDNES (SEQ ID NO: 15), TETSQVAPA (SEQ ID NO: 16), KETAAAKFERQHMDS (SEQ ID NO: 17), MDEKTTGWRGGHVVEGLAGELEQLRARLEHHPQGQREP (SEQ ID NO: 18), SLAELLNAGLGGS (SEQ ID NO: 19), TQDPSRVG (SEQ ID NO: 20), WSHPQFEK (SEQ ID NO: 21), MASMTGGQQMG (SEQ ID NO: 22), EVHTNQDPLD (SEQ ID NO: 23); GKPIPNPLLGLLDST (SEQ ID NO: 24), YTDIEMNRLGK (SEQ ID NO: 25), DLYDDDDK (SEQ ID NO: 26), TDKDMTITFTNKKDAE (SEQ ID NO: 27), AHIVMVDAYKPTK (SEQ ID NO: 28), KLGDIEFIKVNK (SEQ ID NO: 29), KLGSIEFIKVNK (SEQ ID NO: 30), DIPATYEFTDGKHYITNEPIPPK (SEQ ID NO: 31), and DPIVMIDNDKPIT (SEQ ID NO: 32). but not limited to.
[0057] In some embodiments, the CD47 polypeptide monomer includes (eg, is bound to) a ligand. In some embodiments, the ligand is biotin.
[0058] In some embodiments, the CD47 polypeptide monomer comprises the amino acid sequence of SEQ ID NO: 6 (see above). SEQ ID NO: 6 includes, from N-terminus to C-terminus, the amino acid sequence of WT human CD47, a hexahistidine peptide (ie, HHHHHH (SEQ ID NO: 7)), and a 15 amino acid tag GLNDIFEAQKIEWHE (SEQ ID NO: 8). GLNDIFEAQKIEWHE (SEQ ID NO: 8), also known as AVITAG™, is specifically biotinylated by the E. coli biotin ligase BirA. In some embodiments, the CD47 polypeptide monomer comprises, from the N-terminus to the C-terminus, the amino acid sequence of WT human CD47 and a hexahistidine peptide (i.e., HHHHHH (SEQ ID NO: 7)). Contains the amino acid sequence of
[0059] In some embodiments, the CD47 multimer is a homomultimer comprising identical CD47 polypeptide monomers (eg, 2-100 identical CD47 polypeptide monomers as described herein). In some embodiments, the CD47 multimer is a heteromultimer that includes at least two different CD47 polypeptide monomers (eg, CD47 polypeptide monomers described herein). CD47 heteromultimers comprising any combination of two or more different CD47 polypeptide monomers are contemplated.
[0060] In some embodiments, the CD47 polypeptide monomers in a CD47 multimer are linked via peptide bonds, eg, to form a linked chain of CD47 polypeptide monomers. In some embodiments, the CD47 polypeptide monomers in a CD47 multimer are linked via a linker peptide. Exemplary linker peptides include, but are not limited to, for example: LSGX 1 RX 2 X 3 SX 4 DNH (SEQ ID NO: 127) (wherein, X 1 ~X 4 each of which is any naturally occurring amino acid);X 1 SGSRKX 2 RVX 3 X 4 X 5 (SEQ ID NO: 128) (wherein, X 1 ~X 5 each of which is any naturally occurring amino acid); SGRXSA (SEQ ID NO: 129) (wherein X is any naturally occurring amino acid); LSGX 1 RX 2 X 3 SX 4 DNH (SEQ ID NO: 130) (wherein, X 1 ~X 4 each of which is any naturally occurring amino acid);RX 1 X 2 X 3 RKX 4 VX 5 X 6 GX 7 (SEQ ID NO: 137) (wherein, X 1 ~X 7 each of which is any naturally occurring amino acid); RQARXVV (SEQ ID NO: 138) (wherein X is any naturally occurring amino acid); RX 1 X 2 RKVX 3 G (SEQ ID NO: 87) (wherein, X 1 ~X 3 each of which is any naturally occurring amino acid);KRRKQGASRKA(SEQ ID NO:88);LSGX 1 RX 2 X 3 SX 4 DNH (SEQ ID NO: 89) (wherein, X 1 ~X 4 each of which is any naturally occurring amino acid);X 1 X 2 X 3 X 4 X 5 X 6 NX 7 X 8 X 9 (SEQ ID NO. 90) (in the formula, X 1 ~X 9 each of which is any naturally occurring amino acid); AANXL (SEQ ID NO: 91) (wherein X is any naturally occurring amino acid); ATNXL (SEQ ID NO: 139) (wherein X is any naturally occurring amino acid);SISQX 1 YQRSSX 2 X 3 (SEQ ID NO: 92) (wherein, X 1 ~X 3 each of which is any naturally occurring amino acid);SSKLQ(SEQ ID NO: 93);X 1 PX 2 X 3 LIX 4 X 5 X 6 (SEQ ID NO. 94) (wherein, X 1 ~X 6 each of which is any naturally occurring amino acid); GPAX 1 GLX 2 GX 3 (SEQ ID NO. 95) (wherein, X 1 ~X 3 each of which is any naturally occurring amino acid); GPLGIAGQ (SEQ ID NO: 96); PVGLIG (SEQ ID NO: 97); HPVGLLAR (SEQ ID NO: 98); 1 X 2 X 3 VIATX 4 X 5 X 6 X 7 (SEQ ID NO. 99) (wherein, X 1 ~X 7 each of which is any naturally occurring amino acid);X 1 YYVTAX 2 X 3 X 4 X 5 (SEQ ID NO: 100) (wherein, X 1 ~X 5 each of which is any naturally occurring amino acid); PRFKIIGG (SEQ ID NO: 101); PRFRIIGG (SEQ ID NO: 102); SSRHRRALD (SEQ ID NO: 103); RKSSIIIRMRDVVL (SEQ ID NO: 104); SSSFDKGKYKGDDA (SEQ ID NO: 105); SSSFDKGKYKRGDDA (SEQ ID NO: 106); IEGR (SEQ ID NO: 141); IDGR (SEQ ID NO: 140); GGSIDGR (SEQ ID NO: 107); PLGLWA (SEQ ID NO: 108); and DVAQFVLT (SEQ ID NO: 109).
[0061] In some embodiments, the CD47 polypeptide monomers in a CD47 multimer are linked via a linker peptide and at least one spacer. In some embodiments, the spacer comprises 3-200 amino acids. In some embodiments, the spacer includes one or more glycine and / or serine residues. In certain embodiments, the spacer comprises multiple motifs or repeat motifs including GS, GGS, GGGGS (SEQ ID NO: 52), GGSG (SEQ ID NO: 53), or SGGG (SEQ ID NO: 54). In certain embodiments, the spacer is a multiple or repeat motif comprising GSGS (SEQ ID NO: 55), GSGSGS (SEQ ID NO: 56), GSGSGSGS (SEQ ID NO: 57), GSGSGSGSGS (SEQ ID NO: 58), or GSGSGSGSGSGS (SEQ ID NO: 59). including. In some embodiments, the spacer comprises multiple or repeat motifs comprising GGS, such as GGSGGS (SEQ ID NO: 60), GGSGGSGGS (SEQ ID NO: 61), and GGSGGGSGGSGGS (SEQ ID NO: 136). In some embodiments, the spacer comprises multiple or repeating motifs comprising GGSG (SEQ ID NO: 53), GGSGGGSG (SEQ ID NO: 62), or GGSGGGSGGGSG (SEQ ID NO: 63). In some embodiments, the spacer comprises multiple repeats of SEQ ID NO: 52, eg, 2-10 repeats. In some embodiments, the spacer is GENLYFQSGG (SEQ ID NO: 64), SACYCELS (SEQ ID NO: 65), RSIAT (SEQ ID NO: 66), RPACKIPNDLKQKVMNH (SEQ ID NO: 67), GGSAGGSGSGSSGGSSGASGTGTAGGTGSGSGTGSG (SEQ ID NO: 68), AAANSSIDLISVPVDSR (SEQ ID NO: 69). ), or GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS (SEQ ID NO: 70).
[0062] In some embodiments, a CD47 multimer comprises a plurality of CD47 polypeptide monomers (eg, 2-100 CD47 polypeptide monomers) bound to a solid support. In some embodiments, CD47 polypeptide monomers are attached to a solid support via covalent bonding or non-covalent capture. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, a CD47 multimer comprises a plurality of CD47 polypeptide monomers (e.g., two or more CD47 polypeptide monomers) and a solid support, each of the CD47 polypeptide monomers having a , an epitope tag or ligand (e.g., as described above), the capture agent is immobilized on a solid support, and the CD47 polypeptide monomer is epitope-tagged or liganded by the capture agent immobilized on the solid support. is attached to the solid support through specific binding of . In some embodiments, the ligand is biotin and the capture agent is streptavidin. In some embodiments, the CD47 multimer (eg, homomultimer or heteromultimer) comprises streptavidin or avidin bound to 2, 3, or 4 biotinylated CD47 polypeptide monomers. In some embodiments, biotinylated CD47 polypeptide monomers are produced by biotinylating SEQ ID NO: 6, eg, as described in the Examples.
[0063] (b) Method for producing CD47 multimers (i) Recombinant production In some embodiments, a CD47 multimer (e.g., a homomultimer or a heteromultimer comprising at least two CD47 polypeptide monomers linked via a peptide bond or a linker peptide) is produced by a recombinant host cell. generated. Host cell refers to a vehicle that contains the necessary cellular components, such as organelles, necessary to express the CD47 multimers described herein from the corresponding nucleic acids. Nucleic acids can be comprised in nucleic acid vectors that can be introduced into host cells by conventional techniques known in the art (eg, transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, infection, etc.). The choice of nucleic acid vector depends in part on the host cell to be used. Generally, the host cell is either of prokaryotic (eg, bacterial) or eukaryotic (eg, mammalian) origin.
[0064] (A) Nucleic acids, vectors, and host cells Polynucleotide sequences encoding the amino acid sequences of CD47 multimers can be prepared in a variety of ways known in the art. These methods include, but are not limited to, oligonucleotide-mediated (or site-directed) mutagenesis and PCR mutagenesis. Polynucleotide molecules encoding CD47 multimers can be obtained using standard techniques, eg, gene synthesis. In some embodiments, polynucleotide molecules encoding CD47 multimers are mutated to contain specific substitutions using standard techniques in the art, e.g., QUIKCHANGE™ mutagenesis. obtain. Polynucleotides can be synthesized using a nucleotide synthesizer or PCR techniques. A polynucleotide sequence encoding a CD47 multimer can be inserted into a vector capable of replicating and expressing the polynucleotide in a prokaryotic or eukaryotic host cell. Many vectors are available in the art. Each vector may contain various components that can be tailored and optimized for compatibility with a particular host cell. For example, vector components may include, but are not limited to, an origin of replication, a selectable marker gene, a promoter, a ribosome binding site, a signal sequence, a polynucleotide sequence encoding a CD47 multimer, and a transcription termination sequence. . In some embodiments, the vector may include an internal ribosome entry site (IRES) that allows expression of multiple CD47 multimers. Some examples of bacterial expression vectors include pGEX series vectors (e.g., pGEX-2T, pGEX-3X, pGEX-4T, pGEX-5X, pGEX-6P), pET series vectors (e.g., pET-21, pET-21a, pET-21b, pET-23, pET-24), pACYC series vectors (e.g. pACYDuet-1), pDEST series vectors (e.g. pDEST14, pDEST15, pDEST24, pDEST42), and pBR322 and its derivatives. (see, eg, US Pat. No. 5,648,237). Some examples of mammalian expression vectors include, but are not limited to, pCDNA3, pCDNA4, pNICE, pSELECT, and pFLAG-CMV. Other types of nucleic acid vectors include viral vectors for expressing proteins in host cells (eg, baculovirus vectors for expressing proteins in insect host cells).
[0065] In some embodiments, E. coli cells are used as host cells. Examples of E.coli strains include, for example, E.coli 294 (ATCC(R) 31,446), E.coli λ 1776 (ATCC(R) 31,537), E.coli BL21(DE3) (ATCC(R) ) BAA-1025), and E. coli RV308 (ATCC® 31,608). In some embodiments, mammalian cells are used as host cells. Examples of mammalian cell types include, but are not limited to, eg, human embryonic kidney (HEK) cells, Chinese hamster ovary (CHO) cells, HeLa cells, PC3 cells, Vero cells, and MC3T3 cells. Different host cells have characteristic and specific mechanisms for post-translational processing and modification of protein products. Appropriate cell lines or host systems can be chosen to ensure proper modification and processing of the expressed protein. The expression vectors described above can be introduced into suitable host cells using conventional techniques in the art, such as transformation, transfection, electroporation, calcium phosphate precipitation, and direct microinjection. Once a vector is introduced into a host cell for protein production, the host cell is fed with conventional nutrients, appropriately modified for promoter induction, transformant selection, or amplification of the gene encoding the desired sequence. Cultured in medium.
[0066] (B) Protein production, recovery, and purification Host cells used to produce CD47 multimers can be grown in media known in the art and suitable for culturing the selected host cells. Examples of suitable media for bacterial host cells include Luria broth (LB) and necessary adjuvants, such as selective agents, such as ampicillin. Examples of suitable media for mammalian host cells include minimal essential medium (MEM), Dulbecco's modified Eagle's medium (DMEM), DMEM supplemented with fetal bovine serum (FBS), and RPMI-1640. The host cells are cultured at a suitable temperature, eg, about 20°C to about 39°C, eg, 25°C to about 37°C. The pH of the medium is generally from about 6.8 to about 7.4, such as about 7.0, depending primarily on the host organism. When an inducible promoter is used in the expression vector, protein expression is induced under conditions suitable for activation of the promoter. In some embodiments, recovery of CD47 multimers produced by host cells typically involves disruption of the host cells, generally by means such as osmotic shock, sonication, or lysis. Once the cells are disrupted, cell debris can be removed by centrifugation or filtration. In some embodiments, CD47 multimers are secreted into the medium. Supernatants of such expression systems are generally first concentrated using commercially available protein concentration filters, such as Amicon or Millipore Pellicon ultrafiltration units. Protease inhibitors such as PMSF may be included in any of the above steps to inhibit protein degradation, and antibiotics may be included to prevent the growth of foreign contaminants. CD47 multimers may be further purified, eg, by affinity resin chromatography. Standard protein purification methods known in the art can be used. The following procedures are illustrative of suitable purification procedures: fractionation on immunoaffinity or ion exchange columns, ethanol precipitation, reverse phase HPLC, chromatography on silica or cation exchange resins, SOS-PAGE, and gel. filtration.
[0067] (ii) non-covalent capture to a solid support; In some embodiments, CD47 multimers (e.g., CD47 homomultimers or CD47 heteromultimers) can be combined with multiple CD47 polypeptide monomers (e.g., 2-100 CD47 heteromultimers) via non-covalent capture. polypeptide monomers) to a solid support. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, microtiter wells. In some embodiments, the solid support comprises or is made from, for example, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride, or polypropylene. In some embodiments, the CD47 polypeptide monomers each include a ligand, the capture agent is immobilized on a solid support, and the CD47 multimer is immobilized on a solid support. It is produced by attaching a CD47 polypeptide monomer to a solid support through specific binding of a ligand by an agent. In some embodiments, the ligand is biotin and the capture agent is streptavidin. CD47 multimers (e.g., homomultimers or heteromultimers) comprising at least two CD47 polypeptide monomers immobilized on a solid phase or solid support (e.g., a solid phase or solid support described herein). Multimers) are also provided herein. In some embodiments, the CD47 polypeptide monomers are each biotinylated, the streptavidin molecule is immobilized on a solid support, and the CD47 polypeptide monomers are each biotinylated. It is attached to a solid support via a physical bond.
[0068] In some embodiments, the CD47 multimer is produced by culturing a host cell containing a nucleic acid encoding a CD47 polypeptide monomer comprising SEQ ID NO: 6 under suitable conditions that cause expression of the CD47 polypeptide monomer. , prepared by recovering CD47 polypeptide monomer. A CD47 polypeptide monomer containing the amino acid sequence of a biotin receptor peptide is biotinylated using E. coli biotin ligase (BirA). Streptavidin and avidin are tetrameric biotin-binding glycoproteins. Streptavidin and each subunit of avidin have high specificity and high affinity (K D = about 10 -15 ) can bind biotin. In some embodiments, CD47 multimers are produced by attaching biotinylated CD47 polypeptide monomers to a solid support on which streptavidin or avidin molecules are immobilized. In some embodiments, for example, a CD47 multimer comprising a plurality of CD47 polypeptide monomers (e.g., 2-100 CD47 polypeptide monomers) attached to a streptavidin or avidin conjugate solid support. (eg, homomultimers or heteromultimers). Exemplary streptavidin or avidin conjugate solid supports include, for example, gold beads (e.g., available from Nanocs, Nanocomposix, and Cytodiagnostics), gold nanoshells (e.g., available from Nanocs, Nanocomposix, and Cytodiagnostics), dextran polymers (e.g., available from FinaBiosoltions), silica beads (e.g., available from BangsLabs, ThermoFisher, VectorLabs), magnetic beads (e.g., available from CD Bioparticles, ThermoFisher, SigmaAldrich), and sepharose beads (e.g., BioVision and CellSignal). (available from ), but are not limited to these. In some embodiments, a CD47 multimer (e.g., a homomultimer or a heteromultimer) is provided that includes streptavidin or avidin bound to 2, 3, or 4 biotinylated CD47 polypeptide monomers. Ru.
[0069] In some embodiments, CD47 multimers are generated by linking two or more CD47 polypeptide monomers together, eg, via a bifunctional protein coupling agent. Exemplary bifunctional protein coupling agents include, for example, N-succinimidyl-3-(2-pyridyldithiol)propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyladipyl dithiol), midate HCl), active esters (e.g. disuccinimidyl suberate), aldehydes (e.g. glutaraldehyde), bisazide compounds (e.g. bis(p-azidobenzoyl)hexanediamine), bisdiazonium derivatives (e.g. bis- (p-diazoniumbenzoyl)ethylenediamine), diisocyanates (e.g., triene 2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). , but not limited to.
[0070] In some embodiments, CD47 multimers are generated by linking two or more CD47 polypeptide monomers to a solid support, eg, via a bifunctional drug. Commonly used crosslinking agents include, for example, 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g. esters with 4-azidosalicylic acid, 3,3'- Homobifunctional imidoesters including disuccinimidyl esters such as dithiobis(succinimidyl-propionate), difunctional maleimides such as bis-N-maleimido-1,8-octane, and methyl-3-[(p-azidophenyl) )-dithio]propioimidate;
[0071] The CD47 multimers produced as described above are then used in the methods provided herein to prevent interference by drugs that bind to CD47 in serological assays.
[0072] III. How to use SIRP multimers that bind to CD47 to reduce interference in pre-transfusion serological assays (a) Method using SIRP multimer that binds to human CD47 In some embodiments, the method comprises: (a) SIRP multimers that bind human CD47 and do not include an antibody Fc region that binds anti-human globulin (AHG) to reagent RBCs (i.e., specific cell surface antigens); or RBCs known to express a particular cell surface antigen or group of cell surface antigens) and / or reagent platelets (i.e., platelets known to express a particular cell surface antigen or group of cell surface antigens); and (b) after step (a), performing a serological assay on the plasma sample using reagent RBCs and / or reagent platelets, the plasma sample being administered to the subject undergoing treatment with the drug; The drug comprises (i) an antibody Fc region and (ii) a portion that binds human CD47. Such an embodiment is generally shown in FIG. 3A. As shown in Figure 3A, SIRP multimers bind to CD47 expressed on the surface of reagent RBCs (and / or reagent platelets), and the drug binds to reagent RBCs (and / or reagent platelets). interference resulting from drug binding to reagent RBCs and / or reagent platelets (shown in Figure 1B) is minimized (or, in some embodiments, eliminated). ). In some embodiments, about 1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, compared to the amount of drug in the plasma sample from the subject. 5.5x, 6x, 6.5x, 7x, 7.5x, 8x, 8.5x, 9x, 9.5x, 10x, 10.5x, 11x, 11.5x, 12x, 12.5x, 13x, 13.5x CD47 multimer is added to the plasma sample to obtain a 14-fold, 14.5-fold, or 15-fold molar excess of any one of SIRP multimer. In some embodiments, SIRP multimers are added to the subject's plasma and reagent RBCs and / or reagent platelets before the serological assay is performed. In some embodiments, about 1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x compared to the amount of drug in plasma. times, 6.5 times, 7 times, 7.5 times, 8 times, 8.5 times, 9 times, 9.5 times, 10 times, 10.5 times, 11 times, 11.5 times, 12 times, 12.5 times, 13 times, 13.5 times, 14 times, SIRP multimer is added to the plasma sample to obtain a 14.5-fold or 15-fold molar excess of either one of the anti-SIRP multimers.
[0073] In some embodiments, the method comprises: (a) SIRP multimers that bind human CD47 and that do not contain an antibody Fc region that binds anti-human globulin (AHG) from a subject undergoing treatment with a drug; and (b) after step (a), performing a serological assay on the plasma sample using reagent RBCs and / or reagent platelets, wherein the drug comprises ( It contains i) an antibody Fc region and (ii) a portion that binds to human CD47. As shown in Figure 3B, SIRP multimers compete with the drug for binding to CD47 expressed on the surface of reagent RBCs (and / or reagent platelets), thereby allowing the drug to bind to reagent RBCs and / or reagent platelets. / or interference resulting from binding of reagents to platelets (shown in Figure 1B) is minimized (or, in some embodiments, eliminated).
[0074] In some embodiments, the method comprises: (a) SIRP multimers that bind human CD47 but do not include an antibody Fc region that binds anti-human globulin (AHG) from a subject undergoing treatment with a drug; and (b) after step (a), performing a serological assay on the blood sample using the reagent plasma / antiserum, wherein the drug is ) an antibody Fc region; and (ii) a portion that binds to human CD47. As shown in Figure 3C, SIRP multimers compete with the drug for binding to CD47 expressed on the surface of the subject's RBCs and / or platelets, thereby binding to the subject's RBCs and / or platelets. Interference resulting from binding of the drug (shown in Figure 1D) is minimized (or, in some embodiments, eliminated). In some embodiments, the SIRP multimer is added to the reagent plasma / antiserum and blood sample from the subject before the serological assay is performed.
[0075] In some embodiments, the method is performed in solution, eg, where the SIRP multimer is soluble. In some embodiments, the SIRP multimer is immobilized on a solid phase before the method is performed via adsorption to a matrix or surface, covalent binding, or non-covalent binding. In some embodiments, the SIRP multimer is capable of binding to CD47 after immobilization to a solid phase or solid support. The solid phase or solid support used for immobilization is essentially water-insoluble and can be any inert support, surface, or carrier useful in immunoassays, including, for example, surfaces, particles, including supports in the form of porous matrices, cellulose polymer sponges (ImmunoCAP®, Phadia), and the like. Examples of commonly used supports include small sheets, Sephadex, polyvinyl chloride, plastic beads, gold beads, microparticles, assay plates, or test tubes made from polyethylene, polypropylene, polystyrene, and the like. In some embodiments, SIRP multimers are coated onto microtiter plates, such as multiwell microtiter plates, which can be used to analyze multiple samples simultaneously.
[0076] In some embodiments, the portion of the drug that binds human CD47 comprises a wild-type SIRPα, a SIRPα variant, or a CD47-binding fragment of a wild-type SIRPα or a SIRPα variant. In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPα variant (or a CD47-binding fragment thereof), and the SIRPα variant (or a CD47-binding fragment thereof) is a wild-type SIRPα (or a CD47-binding fragment thereof) contains one or more amino acid substitution(s), insertion(s), deletion(s), N-terminal extension(s), and / or C-terminal extension(s) as compared to . In some embodiments, the portion of the drug that binds human CD47 comprises a fragment of a SIRPα variant, and the fragment comprises an extracellular domain of a SIRPα variant.
[0077] In some embodiments, the portion of the drug that binds human CD47 comprises a wild-type SIRPγ, a SIRPγ variant, or a CD47-binding fragment of a wild-type SIRPγ or a SIRPγ variant. In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPγ variant, and the SIRPγ variant comprises one or more amino acid substitution(s), insertion(s), as compared to wild-type SIRPγ. ), deletion(s), N-terminal extension(s), C-terminal extension(s), or a combination of any of the above. In some embodiments, the portion of the drug that binds human CD47 comprises a CD47 binding fragment of a SIRPγ variant, and the fragment comprises an extracellular domain of a SIRPγ variant.
[0078] In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPβ variant capable of binding CD47 (eg, human CD47), or a fragment of a SIRPβ variant capable of binding CD47 (eg, human CD47). In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPβ variant, and the SIRPβ variant comprises one or more amino acid substitution(s), insertion(s), as compared to wild-type SIRPβ. ), deletion(s), N-terminal extension(s), C-terminal extension(s), or a combination of any of the above. In some embodiments, the portion of the drug that binds human CD47 comprises a fragment of a SIRPβ variant, the fragment comprising the extracellular domain of the SIRPβ variant and capable of binding CD47 (eg, human CD47).
[0079] In some embodiments, the drug comprises an anti-CD47 antibody.
[0080] (b) SIRP multimer containing SIRP polypeptide monomer that binds to CD47 In some embodiments, a SIRP multimer that binds human CD47 comprises multiple SIRP polypeptide monomers. In some embodiments, the SIRP multimer has at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or up to 100 SIRP polypeptide monomers. In some embodiments, a "SIRP polypeptide monomer" is a SIRPα polypeptide monomer, a SIRPγ polypeptide monomer, or a SIRPβ variant polypeptide monomer capable of binding CD47 (e.g., human CD47). refers to In some embodiments, the SIRP polypeptide monomer does not include an antibody Fc region. Exemplary SIRPα, SIRPγ, and SIRPβ variant polypeptide monomers are described in further detail below.
[0081] In some embodiments, the SIRP multimer comprises a SIRPα polypeptide monomer that binds human CD47. In some embodiments, the SIRPα polypeptide monomer comprises a fragment of SIRPα (eg, the extracellular domain of wild type SIRPα (“WT SIRPα-ECD”) or the D1 domain thereof) that is capable of binding CD47. In some embodiments, the fragment of SIRPα capable of binding CD47 is a soluble fragment (eg, a fragment of SIRPα that does not include the transmembrane domain or any portion thereof). In some embodiments, the SIRPα polypeptide monomer comprises human SIRPα, mouse SIRPα, rat SIRPα, rhesus SIRPα, cynomolgus monkey SIRPα, or SIRPα of any origin. However, SIRPα is capable of binding CD47 (eg, human CD47 expressed on the surface of reagent RBCs and / or reagent platelets). In some embodiments, the SIRPα polypeptide monomer comprises human SIRPα, mouse SIRPα, rat SIRPα, rhesus SIRPα, cynomolgus monkey SIRPα, or a fragment of SIRPα of any origin. However, the fragment is capable of binding CD47 (eg, human CD47 expressed on the surface of reagent RBCs and / or reagent platelets). In some embodiments, the SIRPα polypeptide monomer comprises a SIRPα variant (or a fragment thereof, eg, a variant of WT SIRPα-ECD or the D1 domain thereof) that is capable of binding CD47 (eg, human CD47). In some embodiments, a SIRPα variant (or fragment thereof) capable of binding CD47 has one or more amino acid substitution(s), deletion(s), insertion(s), as compared to wild-type SIRPα. N-terminal addition(s), and / or C-terminal addition(s). In some embodiments, one or more amino acid substitution(s), deletion(s), insertion(s), N The terminal addition(s) and / or the C-terminal addition(s) alter the glycosylation pattern of the SIRPα variant compared to wild-type SIRPα. In some embodiments, one or more amino acid substitution(s), deletion(s), insertion(s), N-terminus, present in the SIRPα variant (or fragment thereof capable of binding CD47) The addition(s) and / or the C-terminal addition(s) increase the affinity of the SIRPα variant (or fragment thereof (capable of binding CD47)) for human CD47 compared to wild-type SIRPα.
[0082] In some embodiments, the SIRP multimer comprises a SIRPγ polypeptide monomer that binds human CD47. In some embodiments, the SIRPγ polypeptide monomer comprises a fragment of SIRPγ (eg, the extracellular domain of wild type SIRPγ (“WT SIRPγ-ECD”) or the D1 domain thereof) that is capable of binding CD47. In some embodiments, the fragment of SIRPγ that is capable of binding CD47 is a soluble fragment (eg, a fragment of SIRPγ that does not include the transmembrane domain or any portion thereof). In some embodiments, the SIRPγ polypeptide monomer comprises human SIRPγ, mouse SIRPγ, rat SIRPγ, rhesus SIRPγ, cynomolgus monkey SIRPγ, or SIRPγ of any origin. However, SIRPγ is capable of binding to CD47 (eg, human CD47 expressed on the surface of reagent RBCs and / or reagent platelets). In some embodiments, the SIRPγ polypeptide monomer comprises human SIRPγ, mouse SIRPγ, rat SIRPγ, rhesus SIRPγ, cynomolgus monkey SIRPγ, or a fragment of SIRPγ of any origin. However, the fragment is capable of binding CD47 (eg, human CD47 expressed on the surface of reagent RBCs and / or reagent platelets). In some embodiments, the SIRPγ polypeptide monomer is a SIRPγ variant (or fragment thereof, e.g., WT SIRPγ-ECD variant or its D1 domain). In some embodiments, the SIRPγ variant (or fragment thereof (capable of binding CD47)) has one or more amino acid substitution(s), deletion(s), insertions, as compared to wild-type SIRPγ. (s), N-terminal addition(s), and / or C-terminal addition(s). In some embodiments, one or more amino acid substitution(s), deletion(s), insertion(s), N The terminal addition(s) and / or the C-terminal addition(s) alter the glycosylation pattern of the SIRPγ variant compared to wild-type SIRPγ. In some embodiments, one or more amino acid substitution(s), deletion(s), insertion(s), N The terminal addition(s) and / or the C-terminal addition(s) increase the affinity of the SIRPγ variant for human CD47 compared to wild-type SIRPγ.
[0083] In some embodiments, the SIRP multimer comprises a SIRPβ variant polypeptide monomer that binds human CD47, or a fragment thereof that binds human CD47. In some embodiments, a fragment of a SIRPβ variant polypeptide monomer capable of binding CD47 is a soluble fragment (eg, a fragment of a SIRPβ variant polypeptide that does not include the transmembrane domain or any portion thereof). In some embodiments, the SIRPβ variant polypeptide monomer has one or more amino acid substitution(s), deletion(s), insertion(s), N terminal addition(s), and / or C-terminal addition(s), which increases the affinity of the SIRPβ variant polypeptide monomer for human CD47 compared to wild-type SIRPβ. In some embodiments, the SIRPβ variant polypeptide monomer comprises a fragment of a SIRPβ variant (eg, the extracellular domain of a SIRPβ variant or its D1 domain) that is capable of binding CD47. In some embodiments, a fragment of a SIRPβ variant capable of binding CD47 is a soluble fragment (eg, a fragment of a SIRPβ variant that does not include the transmembrane domain or any portion thereof). In some embodiments, the SIRPβ variant polypeptide monomer is a variant of wild-type human SIRPβ, a variant of wild-type mouse SIRPβ, a variant of wild-type rat SIRPβ, a variant of wild-type rhesus macaque SIRPβ, a variant of wild-type cynomolgus monkey SIRPβ , or containing SIRPβ variants of any origin. However, the SIRPβ variant is capable of binding CD47 (eg, human CD47 expressed on the surface of reagent RBCs and / or reagent platelets). In some embodiments, the SIRPβ variant polypeptide monomer is a variant of wild-type human SIRPβ, a variant of wild-type mouse SIRPβ, a variant of wild-type rat SIRPβ, a variant of wild-type, a variant of wild-type rhesus SIRPβ, a wild-type or a fragment of a SIRPβ variant of any origin. However, the fragment is capable of binding CD47 (eg, human CD47 expressed on the surface of reagent RBCs and / or reagent platelets). In some embodiments, one or more amino acid substitution(s), deletion(s), insertion(s) present in the SIRPβ variant polypeptide monomer (or fragment thereof capable of binding CD47) ), N-terminal addition(s), and / or C-terminal addition(s) alter the glycosylation pattern of the SIRPβ variant polypeptide monomer compared to wild-type SIRPβ.
[0084] In some embodiments, the SIRPα polypeptide monomer, SIRPβ variant polypeptide monomer, or SIRPγ polypeptide monomer comprises an amino acid sequence of any one of SEQ ID NOs: 33-41 below. EEELQIIQPD KSVLVAAGET ATLRCTITSL FPVGPIQWFR GAGPGRVLIY NQRQGPFPRV TTVSDTTKRN NMDFSIRIGA ITPADAGTYY CIKFRKGSPD DVEFKSGAGT ELSVRAKPS (SEQ ID NO: 33) EEELQIIQPD KSVLVAAGET ATLRCTITSL FPVGPIQWFR GAGPGRELIY NQREGPFPRV TTVSDTTKRN NMDFSIRIGA ITPADAGTYY CVKFRKGSPD DVEFKSGAGT ELSVRAKPS (SEQ ID NO: 34) EEELQIIQPD KSVLVAAGET ATLRCTITSL FPVGPIQWFR GAGPGRVLIY NQREGPFPRV TTVSDTTKRN NMDFSIRIGA ITPADAGTYY CIKFRKGSPD DVEFKSGAGT ELSVRAKPS (SEQ ID NO: 35) EDELQIIQPE KSVSVAAGES ATLRCAITSL FPVGPIQWFR GAGAGRVLIY NQRQGPFPRV TTVSETTKRN NLDFSISISN ITPADAGTYY CIKFRKGSPD DVEFKSGAGT ELSVRAKPS (SEQ ID NO: 36) EEELQIIQPD KSISVAAGES ATLHCTITSL FPVGPIQWFR GAGPGRVLIY NQRQGPFPRV TTVSDTTKRN NMDFSIRISN ITPADAGTYY CIKFRKGSPD DVEFKSGAGT ELSVRAKPS (SEQ ID NO: 37) EEELQIIQPE KLLLVTVGKT ATLHCTITSL FPVGPIQWFR GVGPGRVLIY NQRDGPFPRV TTVSDGTKRN NMDFSIRISS ITPADVGTYY CVKFRKGTPE DVEFKSGPGT EMALGAKPS (SEQ ID NO: 38) EEELQIIQPE KLLLVTVGKT ATLHCTITSL FPVGPIQWFR GVGPGRVLIY NQKDGPFPRV TTVSDGTKRN NMDFSIRISS ITPADVGTYY CVKFRKGSPE DVEFKSGPGT EMALGAKPS (SEQ ID NO: 39) EEELQIIQPE KLLLVTVGKT ATLHCTITSL FPVGPIQWFR GVGPGRVLIY NQKDGHFPRV TTVSDGTKRN NMDFSIRISS ITPADVGTYY CVKFRKGSPE DVEFKSGPGT EMALGAKPS (SEQ ID NO: 40) EEELQIIQPE KLLLVTVGKT ATLHCTITSH FPVGPIQWFR GVGPGRVLIY NQKDGHFPRV TTVSDGTKRN NMDFSIRISS ITPADVGTYY CVKFRKGSPE DVEFKSGPGT EMALGAKPS (SEQ ID NO: 41) EEELQIIQPE KLLLVTVGKT ATLHCTITSL FPVGPVLWFR GVGPGRVLIY NQRQGPFPRV TTVSDTTKRN NMDFSIRISS ITPADVGTYY CVKFRKGTPE DVEFKSGPGT EMALGAKPS (SEQ ID NO: 42) EEELQIIQPE KLLLVTVGKT ATLHCTITSL FPVGPIQWFR GVGPGRELIY NAREGRFPRV TTVSDLTKRN NMDFSIRISS ITPADVGTYY CVKFRKGSPE DVEFKSGPGT EMALGAKPS (SEQ ID NO: 43) EEELQIIQPE KLLLVTVGKT ATLHCTITSL LPVGPIQWFR GVGPGRELIY NQRDGPFPRV TTVSDGTKRN NMDFSIRISS ITPADVGTYY CVKFRKGTPE DVEFKSGPGT EMALGAKPS (SEQ ID NO: 44) EEELQIIQPD KSVLVAAGET ATLRCTITSL FPVGPIQWFR GAGPGRVLIY NQRQGPFPRV TTVSDTTKRN NMDFSIRIGN ITPADAGTYY CIKFRKGSPD DVEFKSGAGT ELSVRAKPS (SEQ ID NO: 45)
[0085] Exemplary SIRPα polypeptide monomers (e.g., SIRPα variants), SIRPβ variant polypeptide monomers, and SIRPγ polypeptide monomers (e.g., , SIRPγ variant) for further details on WO2013 / 109752;US2015 / 0071905;USP9,944,911;WO2016 / 023040;WO2017 / 027422;US2017 / 0107270;USP10,259,859;US9845345;WO2016187226 ;US20180155405;WO2017177333;WO2014094122;US2015329616;US20180312563 ; WO2018176132; WO2018081898; WO2018081897; US20180141986A1; and EP3287470A1, the contents of which are incorporated herein by reference in their entirety.
[0086] In some embodiments, the SIRP polypeptide monomer comprises a fusion polypeptide that includes a multimerization domain, including, but not limited to, the exemplary multimerization domains described above for CD47 polypeptide monomers. include.
[0087] In some embodiments, the SIRP polypeptide monomer comprises a fusion polypeptide comprising a multimerization domain set forth in any one of SEQ ID NOs: 33-45 and any one of SEQ ID NOs: 81-83. . In some embodiments, the SIRP polypeptide monomer is WO2013 / 109752;US2015 / 0071905;USP9,944,911;WO2016 / 023040;WO2017 / 027422;US2017 / 0107270;USP10,259,859;US9845345;WO201618 7226;US20180155405;WO2017177333 ;WO2014094122;US2015329616;US20180312563;WO2018176132;WO2018081898;WO2018081897;US20180141986A1; and EP3287470A1, and the SIRP polypeptide monomer disclosed in any one of; Multimerization according to any one of 3. a fusion polypeptide comprising a domain. In some embodiments, the SIRP polypeptide monomer comprises a fusion polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 110. EEELQIIQPD KSVLVAAGET ATLRCTITSL FPVGPIQWFR GAGPGRVLIY NQRQGPFPRV TTVSDTTKRN NMDFSIRIGN ITPADAGTYY CIKFRKGSPD DVEFKSGAGT ELSVRAKPSA KTTAPSVYPL APVCGDTTGS SVTLGCLVKG YFPEPVTLTW NSGSLSSGVH TFPAVLQSDL YTLSSSVTVT SSTWPSQSIT CNVAHP ASST KVDKKIEPRG PTIKPCPPCK CPAPNLLGGP SVFIFPPKIK DVLMISLSPI VTCVVVDVSE DDPDVQISWF VNNVEVHTA QTQTHREDYN STLRVVSALP IQHQDWMSGK EFKCKVNNKD LPAPIERTIS KPKGSVRAPQ VYVLPPPEEE MTKKQVTLTC MVTDFMPEDI YVEWTNNGKT ELNYKNTEPV LDSDGSYFMY SKLRVEKKNW VERNSYSCSV VHEGLHNHHT TKSFSRTPG (SEQ ID NO: 110) .
[0088] In some embodiments, the SIRP polypeptide monomer (eg, fusion polypeptide) includes (eg, further includes) an epitope tag. In some embodiments, the epitope tag promotes multimerization of SIRP polypeptide monomers. In some embodiments, the tag facilitates immobilization of the SIRP polypeptide monomer to a solid support (eg, bead, glass surface, etc.). Exemplary epitope tags include, but are not limited to, SEQ ID NOs: 7-32 above for CD47 polypeptide monomers.
[0089] In some embodiments, a SIRP polypeptide monomer comprises (eg, is attached to) a ligand. In some embodiments, the ligand is biotin.
[0090] In some embodiments, the SIRP polypeptide monomer comprises the amino acid sequence of SEQ ID NO: 111 (see below). SEQ ID NO: 111 includes, from the N-terminus to the C-terminus, the amino acid sequence of SEQ ID NO: 45, a hexahistidine peptide (ie, HHHHHH (SEQ ID NO: 7)), and a 15 amino acid tag GLNDIFEAQKIEWHE (SEQ ID NO: 8). GLNDIFEAQKIEWHE (SEQ ID NO: 8), also known as AVITAG™, is specifically biotinylated by the E. coli biotin ligase BirA. In some embodiments, the CD47 polypeptide monomer comprises, from N-terminus to C-terminus, the amino acid sequence of SEQ ID NO: 45 and a hexahistidine peptide (i.e., HHHHHH (SEQ ID NO: 7)). (see below). EEELQIIQPD KSVLVAAGET ATLRCTITSL FPVGPIQWFR GAGPGRVLIY NQRQGPFPRV TTVSDTTKRN NMDFSIRIGN ITPADAGTYY CIKFRKGSPD DVEFKSGAGT ELSVRAKPSH HHHHHGLNDI FEAQKIEWHE (SEQ ID NO: 111) EEELQIIQPD KSVLVAAGET ATLRCTITSL FPVGPIQWFR GAGPGRVLIY NQRQGPFPRV TTVSDTTKRN NMDFSIRIGN ITPADAGTYY CIKFRKGSPD DVEFKSGAGT ELSVRAKPSH HHHHH (SEQ ID NO: 112)
[0091] In some embodiments, the SIRP multimers that bind human CD47 are the same SIRP polypeptide monomers (e.g., the same SIRPα polypeptide monomers, the same SIRPβ variant polypeptide monomers, or the same SIRPγ polypeptide monomers, such as the SIRP polypeptide monomers described herein). In some embodiments, the SIRP multimer that binds human CD47 comprises at least two different SIRPα polypeptide monomers, two different SIRPβ variant polypeptide monomers, two different SIRPγ polypeptide monomers, or A heteromultimer containing any combination of the above. Any combination of two or more different SIRPα polypeptide monomers, SIRPβ variant polypeptide monomers, and / or SIRPγ polypeptide monomers (e.g., the SIRP polypeptide monomers described herein) SIRP heteromultimers are contemplated.
[0092] In some embodiments, the SIRP polypeptide monomers in a SIRP multimer are linked via a peptide bond or a linker peptide, eg, to form a linked chain of SIRP polypeptide monomers. In some embodiments, the SIRP polypeptide monomers in a SIRP multimer are linked via a linker peptide. Exemplary linker peptides include, but are not limited to, those set forth in SEQ ID NOs: 85-109, 127-130, 140, and 141, as well as other linkers used in CD47 multimers (see above). . In some embodiments, the SIRP polypeptide monomers in a SIRP multimer are linked via a peptide linker and at least one spacer. Exemplary peptide spacers include, but are not limited to, SEQ ID NOs: 52-70, and other spacers used in CD47 multimers (see above).
[0093] In some embodiments, a SIRP multimer that binds human CD47 comprises a plurality of SIRP polypeptide monomers (eg, 2-100 SIRP polypeptide monomers) attached to a solid support. In some embodiments, SIRP polypeptide monomers are attached to a solid support via covalent bonding or non-covalent capture. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, the solid support comprises or is made from, for example, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride, or polypropylene. In some embodiments, a SIRP multimer that binds human CD47 comprises a plurality of SIRP polypeptide monomers (e.g., two or more SIRP polypeptide monomers) and a solid support; each of the molecules comprises an epitope tag or ligand (e.g., as described above), the capture agent is immobilized on a solid support, and the SIRP polypeptide monomer is a capture agent immobilized on the solid support. is attached to a solid support through specific binding of an epitope tag or ligand. In some embodiments, the ligand is biotin and the capture agent is streptavidin. In some embodiments, the SIRP multimer (eg, homomultimer or heteromultimer) comprises streptavidin or avidin bound to 2, 3, or 4 biotinylated SIRP polypeptide monomers.
[0094] (c) Method for producing SIRP multimers. In some embodiments, SIRP multimers (e.g., homomultimers or heteromultimers comprising at least two SIRP polypeptide monomers linked via a peptide bond or a linker peptide) are produced by a recombinant host cell. generated. Any of the methods described herein for producing CD47 multimers using recombinant techniques are similarly applicable to producing SIRP multimers, including SIRP polypeptide monomers.
[0095] In some embodiments, a SIRP multimer (e.g., a homomultimer or a heteromultimer) can bind multiple SIRP polypeptide monomers (e.g., 2-100 SIRP polypeptides) via non-covalent capture. monomers) to a solid support. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, the SIRP polypeptide monomers each include a ligand, the capture agent is immobilized on a solid support, and the SIRP multimer is a capture agent immobilized on a solid support. It is produced by attaching a SIRP polypeptide monomer to a solid support through specific binding of a ligand by an agent. In some embodiments, the ligand is biotin and the capture agent is streptavidin.
[0096] Any of the methods described elsewhere herein for binding CD47 polypeptide monomers to a solid support to produce CD47 multimers also applies to binding SIRP polypeptide monomers to a solid support. It can be applied to generate SIRP multimers. For example, in some embodiments, the SIRP multimer allows the host cell to contain a nucleic acid encoding a SIRP polypeptide monomer comprising SEQ ID NO: 111 under appropriate conditions to cause expression of the SIRP polypeptide monomer. It is prepared by culturing and collecting SIRP polypeptide monomers. A SIRP polypeptide monomer containing the amino acid sequence of a biotin receptor peptide is biotinylated using E. coli biotin ligase (BirA). In some embodiments, SIRP multimers are produced by attaching biotinylated SIRP polypeptide monomers to a solid support on which streptavidin or avidin molecules are immobilized. In some embodiments, for example, a SIRP multimer comprising a plurality of SIRP polypeptide monomers (e.g., 2-100 SIRP polypeptide monomers) attached to a streptavidin or avidin conjugate solid support. (eg, homomultimers or heteromultimers). Exemplary streptavidin or avidin conjugate solid supports are described in further detail elsewhere herein. In some embodiments, a SIRP multimer (e.g., a homomultimer or a heteromultimer) comprising streptavidin or avidin bound to 2, 3, or 4 biotinylated SIRP polypeptide monomers is provided. Ru.
[0097] In some embodiments, SIRP multimers link one or more SIRP monomer polypeptides using a bifunctional crosslinker (e.g., as described elsewhere herein). , for example, to a solid support or, for example, by bonding to each other.
[0098] The SIRP multimers thus produced are then used in the methods provided herein to prevent interference by drugs that bind to CD47 in serological assays.
[0099] IV. How to use anti-SIRP multimers to reduce interference in pre-transfusion serological assays (a) Method using anti-SIRP multimers that bind to drugs In some embodiments, the method comprises: (a) administering an anti-SIRP multimer that binds to a drug (i.e., a moiety of the drug that includes a moiety that binds human CD47) to plasma from a subject undergoing treatment with the drug; (b) after step (a), reagent RBCs (i.e. RBCs known to express a particular cell surface antigen or group of cell surface antigens) and / or reagent platelets (i.e. , performing a serological assay on a plasma sample using platelets known to express a particular cell surface antigen or group of cell surface antigens), wherein the drug comprises (i) an antibody Fc region; and (ii) a portion that binds to human CD47. Such an embodiment is generally shown in FIG. 3D. As shown in Figure 3D, the anti-SIRP multimer binds to the drug (e.g., the portion of the drug that binds human CD47) in the subject's plasma sample, and the drug binds to reagent RBCs and / or reagent platelets. Block out what you do. Little or no drug can bind to CD47 on the surface of reagent RBCs and / or reagent platelets. Interferences resulting from drug binding to reagent RBCs and / or reagent platelets (shown in Figure 1B) are minimized (or, in some embodiments, eliminated), thereby reducing serological False positive results in assays are prevented. In some embodiments, about 1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x compared to the amount of drug in plasma. times, 6.5 times, 7 times, 7.5 times, 8 times, 8.5 times, 9 times, 9.5 times, 10 times, 10.5 times, 11 times, 11.5 times, 12 times, 12.5 times, 13 times, 13.5 times, 14 times, Anti-SIRP multimer is added to the plasma sample to obtain a 14.5-fold or 15-fold molar excess of either one of the anti-SIRP multimers. In some embodiments, an anti-SIRP multimer that binds the drug is also added to the reagent RBCs and / or reagent platelets before the serological assay is performed. In some embodiments, anti-SIRP multimers are added to reagent RBCs and / or reagent platelets (eg, reagent RBCs and / or reagent platelets only) before the serological assay is performed.
[0100] In some embodiments, the method is performed in solution, eg, where the anti-SIRP multimer that binds the drug is soluble. In some embodiments, the anti-SIRP multimer that binds the drug is immobilized on a solid phase before the method is performed via adsorption to a matrix or surface, covalent binding, or non-covalent binding. In some embodiments, an anti-SIRP multimer that binds a drug is capable of binding the drug after immobilization to a solid phase or solid support. The solid phase or solid support used for immobilization is essentially water-insoluble and can be any inert support, surface, or carrier useful in immunoassays, including, for example, surfaces, particles, including supports in the form of porous matrices, cellulose polymer sponges (ImmunoCAP®, Phadia), and the like. Examples of commonly used supports include small sheets, Sephadex, polyvinyl chloride, plastic beads, gold beads, microparticles, assay plates, or test tubes made of polyethylene, polypropylene, polystyrene, and the like. In some embodiments, anti-SIRP multimers that bind drugs are coated onto microtiter plates, such as multiwell microtiter plates that can be used to analyze multiple samples simultaneously.
[0101] In some embodiments, the portion of the drug that binds human CD47 comprises a wild-type SIRPα, a SIRPα variant, or a CD47-binding fragment of a wild-type SIRPα or a SIRPα variant. In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPα variant (or a CD47-binding fragment thereof), and the SIRPα variant (or a CD47-binding fragment thereof) is a wild-type SIRPα (or a CD47-binding fragment thereof) contains one or more amino acid substitution(s), insertion(s), deletion(s), N-terminal extension(s), and / or C-terminal extension(s) as compared to . In some embodiments, the portion of the drug that binds human CD47 comprises a fragment of a SIRPα variant, and the fragment comprises an extracellular domain of a SIRPα variant.
[0102] In some embodiments, the portion of the drug that binds human CD47 comprises a wild-type SIRPγ, a SIRPγ variant, or a CD47-binding fragment of a wild-type SIRPγ or a SIRPγ variant. In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPγ variant, and the SIRPγ variant comprises one or more amino acid substitution(s), insertion(s) as compared to wild-type SIRPγ. ), deletion(s), N-terminal extension(s), C-terminal extension(s), or a combination of any of the above. In some embodiments, the portion of the drug that binds human CD47 comprises a CD47 binding fragment of a SIRPγ variant, and the fragment comprises an extracellular domain of a SIRPγ variant.
[0103] In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPβ variant capable of binding CD47 (eg, human CD47), or a fragment of a SIRPβ variant capable of binding CD47 (eg, human CD47). In some embodiments, the portion of the drug that binds human CD47 comprises a SIRPβ variant, and the SIRPβ variant comprises one or more amino acid substitution(s), insertion(s), as compared to wild-type SIRPβ. ), deletion(s), N-terminal extension(s), C-terminal extension(s), or a combination of any of the above. In some embodiments, the portion of the drug that binds human CD47 comprises a fragment of a SIRPβ variant, the fragment comprising the extracellular domain of the SIRPβ variant and capable of binding CD47 (eg, human CD47).
[0104] (b) Anti-SIRP multimer In some embodiments, the anti-SIRP multimer that binds a drug comprises an anti-SIRP antibody (or drug-binding fragment thereof) that is capable of binding to a SIRPα, SIRPα variant, SIRPβ variant, SIRPγ, or SIRPγ variant portion of the drug. In some embodiments, the anti-SIRP multimer that binds the drug is one or more anti-SIRP antibodies (or drug-binding fragments thereof) that are capable of binding to the SIRPα, SIRPα variant, SIRPβ variant, SIRPγ, or SIRPγ variant portion of the drug. )including. In some embodiments, the anti-SIRP multimer is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, Contains 55, 60, 65, 70, 75, 80, 85, 90, 95, or up to 100 anti-SIRP antibodies (or drug-binding fragments thereof). In some embodiments, the anti-SIRP multimer comprises (eg, is) a bivalent anti-SIRP antibody. In some embodiments, "anti-SIRP antibody" refers to an antibody or drug-binding fragment thereof (eg, an antigen-binding fragment thereof) that specifically binds to SIRPα, SIRPα variant, SIRPγ, SIRPγ variant, or SIRPβ variant. The extracellular domains of SIRPα, SIRPβ, and SIRPγ have high homology. Thus, in some embodiments, "anti-SIRP antibody" refers to an antibody or drug-binding fragment thereof that is capable of cross-reacting with one or more of SIRPα, SIRPα variant, SIRPγ, SIRPγ variant, and / or SIRPβ variant. Point.
[0105] In some embodiments, the anti-SIRP multimer comprises a full-length anti-SIRP antibody. In some embodiments, the anti-SIRP antibody comprises an Fc region (or portion thereof) that does not bind anti-human globulin reagent (AHG). (Further details regarding serological assays and reagents used in such assays are provided elsewhere herein). In some embodiments, the anti-SIRP antibody comprises a mouse Fc region (or portion thereof). In some embodiments, the mouse Fc region comprises the amino acid sequence set forth in any one of SEQ ID NOs: 81-83. In some embodiments, drug-binding fragments (e.g., antigen-binding fragments) of anti-SIRP antibodies include, but are not limited to, Fab, Fab', F(ab') 2 , Fab'-SH, Fv, diabody, one-arm antibody, scFv, scFv-Fc, single domain antibody, single heavy chain antibody, etc. In some embodiments, the anti-SIRP antibody (or drug-binding fragment thereof) is an ADA (anti-drug antibody) that binds to a drug (i.e., SIRPα, a SIRPα variant, a SIRPβ variant, SIRPγ, or a portion of a drug that includes a SIRPγ variant). ) or NAb (neutralizing antibody). In some embodiments, the affinity of the drug for anti-SIRP antibodies is greater than the affinity of the drug for human CD47. In some embodiments, the anti-SIRP antibody (or drug binding fragment thereof) has a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 47. including. In some embodiments, the anti-SIRP antibody (or drug binding fragment thereof) has a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 48 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 49. including. In some embodiments, the anti-SIRP antibody (or drug binding fragment thereof) has a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 50 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 51. including. In some embodiments, the anti-SIRP antibody (or drug binding fragment thereof) has a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 113 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 114. including. In some embodiments, the anti-SIRP antibody (or drug binding fragment thereof) has a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 115 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 116. including. In some embodiments, the anti-SIRP antibody (or drug binding fragment thereof) has a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 133 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 134. including. In some embodiments, the anti-SIRP antibody comprises a mouse Fc domain comprising the amino acid sequence set forth in any one of SEQ ID NOs: 81-83. In some embodiments, the drug-binding fragment of an anti-SIRP antibody is, e.g., Fab, Fab', F(ab') 2 , Fab'-SH, Fv, diabody, one-arm antibody, scFv, scFv-Fc, single domain antibody, single heavy chain antibody, etc. In some embodiments, the drug binding fragment of an anti-SIRP antibody comprises a Fab or F(ab')2 comprising SEQ ID NO: 131 and SEQ ID NO: 132. DVQLVESGGG VVRPGESLRL SCAASGFSFS SYAMNWVRQA PGEGLEWVSR INSGGGGTDY AESVKGRFTI SRDNSENTLY LQMNSLRAED TAVYYCAKQY DWNSFFDYWG LGALVTVSS (SEQ ID NO: 46) ETVLTQSPAT LSVSPGERAT LSCRASQTVG SKLAWHQQKP GQAPRLLIYD ATNRATGISD RFSGSGSGTD FTLTISSLQT EDSAVYYCQQ YYYWPPYRFG GGTKVEIK (SEQ ID NO: 47) DVQLVESGGG VVRPGESLRL SCEASGFTFS SNAMSWVRQA PGKGLEWVAG ISSGSDTYYG DSVKGRLTIS RDNSKNILYL QMNSLTAEDT AVYYCARETW NHLFDYWGQG TLVTVSS (SEQ ID NO: 48) SYELTQPPSV SVSPGQTARI TCSGGSYSSY YYAWYQQKPG QAPVTLIYSD DKRPSNIPER FSGSSSGTTV TLTISGVQAE DEADYYCGGY DQSSYTNPFG GGTKLTVL (Sequence number 49) DVQLVESGGG VVRPGESLRL SCAASGFTFS SYDMNWVRQA PGEGLEWVSL ISGSGEIIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKEN NRYRFFDDWG QGTLVTVSS (SEQ ID NO: 50) ETVLTQSPGT LTLSPGERAT LTCRASQSVY TYLAWYQEKP GQAPRLLIYG ASSRATGIPD RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YYDRPPLTFG GGTKVEIK (SEQ ID NO: 51) DVQLVESGGG VVRPGESLRL SCAASGFTFS SYAMSWVRQA PGKGLEWLAG ISAGGSDTYY IDSVKGRFTI SRDNPKNSLY LQMSSLTAED TAVYYCARET WNHLFDYWGL GTLVTVSS (SEQ ID NO: 113) ALTQPASVSA NPGETVKITC SGGDYYSTYY AWYQQKSPGS APVTVIHSDD KRPSDIPSRF SGSASGSAAT LIITGVRVED EAVYYCGGYD GRTYINTFGA GTTLTVL (SEQ ID NO: 114) DVQLVESGGG VVRPGESLRL SCAASGFTFS SNAMSWVRQA PGKGLEWLAG ISAGGSDTYY PASVKGRFTI SRDNSKNTLY LQMNTLTAED TAVYYCARET WNHLFDYWGL GTLVTVSS (SEQ ID NO: 115) ALTQPASVSA NPGETVKIAC SGGDYYSYYY GWYQQKAPGS ALVTVIYSDD KRPSDIPSRF SGSASGSTAT LTITGVRAED EAVYYCGGYD YSTYANAFGA GTTLTVL (SEQ ID NO: 116) DVQLVESGGG VVRPGESLRL SCEASGFTFS SNAMSWVRQA PGKGLEWVAG ISSGSDTYYG DSVKGRLTIS RDNSKNILYL QMNSLTAEDT AVYYCARETW NHLFDYWGLG TLTVVS (SEQ ID NO: 133) ALTQPASVSA SPGETVEITC SGGSDSSYYY GWYQQKSPGS APVTVIYSDN KRPSNIPSRF SGSASGSTAT LTITGVRVED EAVYYCGGYD YSTYTNPFGA GTTLTVL (SEQ ID NO: 134) DVQLVESGGG VVRPGESLRL SCEASGFTFS SNAMSWVRQA PGKGLEWVAG ISSGSDTYYG DSVKGRLTIS RDNSKNILYL QMNSLTAEDT AVYYCARETW NHLFDYWGLG TLVTVSSAKT TAPSVYPLAP VCGDTTGSSV TLGCLVKGYF PEPVTLTWNS GSLSSGVHTF PAVLQSDLYT LSSSVTVTSS TWPSQS ITCN VAHPASSTKV DKKIEPRGPT IKPCPPCKCP GSGSHHHHHH GLNDIFEAQK IEWHE (SEQ ID NO: 131) ALTQPASVSA SPGETVEITC SGGSDSSYYY GWYQQKSPGS APVTVIYSDN KRPSNIPSRF SGSASGSTAT LTITGVRVED EAVYYCGGYD YSTYTNPFGA GTTLTVLRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC (Sequence number 132)
[0106] In some embodiments, the anti-SIRP antibody comprises a heavy chain comprising SEQ ID NO: 117 and a light chain comprising SEQ ID NO: 118. In some embodiments, the anti-SIRP antibody comprises a heavy chain comprising SEQ ID NO: 119 and a light chain comprising SEQ ID NO: 118. In some embodiments, the anti-SIRP antibody comprises a heavy chain comprising SEQ ID NO: 120 and a light chain comprising SEQ ID NO: 121. In some embodiments, the anti-SIRP antibody comprises a heavy chain comprising SEQ ID NO: 122 and a light chain comprising SEQ ID NO: 121. The amino acid sequences of SEQ ID NOs: 117-122 are provided below. DVQLVESGGG VVRPGESLRL SCAASGFTFS SNAMSWVRQA PGKGLEWLAG ISAGGSDTYY PASVKGRFTI SRDNSKNTLY LQMNTLTAED TAVYYCARET WNHLFDYWGL GTLVTVSSAK TTPPSVYPLA PGSAAQTNSM VTLGCLVKGY FPEPVTVTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVPS STWPSETVTC NVA HPASSTK VDKKIVPRDC GCKPCICTVP EVSSVFIFPP KPKDVLTITL TPKVTCVVVD ISKDDPEVQF SWFVDDVEVH TAQTQPREEQ FASTFRSVSE LPIMHQDWLN GKEFKCRVNS AAFPAPIEKT ISKTKGRPKA PQVYTIPPPK EQMAKDKVSL TCMITDFFPE DITVEWQWNG QPAENYKNTQ P IMDTDGSYF IYSKLNVQKS NWEAGNTFTC SVLHEGLHNH HTEKSLSHSP G (SEQ ID NO: 117) ALTQPASVSA NPGETVKIAC SGGDYYSYYY GWYQQKAPGS ALVTVIYSDD KRPSDIPSRF SGSASGSTAT LTITGVRAED EAVYYCGGYD YSTYANAFGA GTTLTVLGQP KSSPSVTLFP PSSEELETNK ATLVCTITDF YPGVVTVDWK VDGTPVTQGM ETTQPSKQSN NKYMASSYLT LTARAWERHS SYSCQVTHEG HTVEKSLSRA DCS (Sequence number 118) DVQLVESGGG VVRPGESLRL SCAASGFTFS SNAMSWVRQA PGKGLEWLAG ISAGGSDTYY PASVKGRFTI SRDNSKNTLY LQMNTLTAED TAVYYCARET WNHLFDYWGL GTLVTVSSAK TTAPSVYPLA PVCGDTTGSS VTLGCLVKGY FPEPVTLTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVTS STWPSQSITC N VAHPASSTK VDKKIEPRGP TIKCPPCKC PAPNLLGGPS VFIFPPKIKD VLMISLSPIV TCVVVDVSED DPDVQISWFV NNVEVHTAQT QTHREDYNST LRVVSALPIQ HQDWMSGKEF KCKVNNKDLP APIERTISKP KGSVRAPQVY VLPPPEEEMT KKQVTLTCMV TDFMPEDIYV EWTNNGKTEL NYKNTEPVLD SDGSYFMYSK LRVEKKNWVE RNSYSCSVVH EGLHNHHTTK SFSRTPG (SEQ ID NO: 119) DVQLVESGGG VVRPGESLRL SCAASGFTFS SYAMSWVRQA PGKGLEWLAG ISAGGSDTYY IDSVKGRFTI SRDNPKNSLY LQMSSLTAED TAVYYCARET WNHLFDYWGL GTLVTVSSAK TTPPSVYPLA PGSAAQTNSM VTLGCLVKGY FPEPVTVTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVPS STWPSETVTC NVA HPASSTK VDKKIVPRDC GCKPCICTVP EVSSVFIFPP KPKDVLTITL TPKVTCVVVD ISKDDPEVQF SWFVDDVEVH TAQTQPREEQ FASTFRSVSE LPIMHQDWLN GKEFKCRVNS AAFPAPIEKT ISKTKGRPKA PQVYTIPPPK EQMAKDKVSL TCMITDFFPE DITVEWQWNG QPAENYKNTQ P IMDTDGSYF IYSKLNVQKS NWEAGNTFTC SVLHEGLHNH HTEKSLSHS PG (SEQ ID NO: 120) ALTQPASVSA NPGETVKITC SGGDYYSTYY AWYQQKSPGS APVTVIHSDD KRPSDIPSRF SGSASGSAAT LIITGVRVED EAVYYCGGYD GRTYINTFGA GTTLTVLGQP KSSPSVTLFP PSSEELETNK ATLVCTITDF YPGVVTVDWK VDGTPVTQGM ETTQPSKQSN NKYMASSYLT LTARAWERHS SYSCQVTHEG HT VEKSLSRA DCS (Sequence number 121) DVQLVESGGG VVRPGESLRL SCAASGFTFS SYAMSWVRQA PGKGLEWLAG ISAGGSDTYY IDSVKGRFTI SRDNPKNSLY LQMSSLTAED TAVYYCARET WNHLFDYWGL GTLVTVSSAK TTAPSVYPLA PVCGDTTGSS VTLGCLVKGY FPEPVTLTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVTS STWPSQSITC N VAHPASSTK VDKKIEPRGP TIKCPPCKC PAPNLLGGPS VFIFPPKIKD VLMISLSPIV TCVVVDVSED DPDVQISWFV NNVEVHTAQT QTHREDYNST LRVVSALPIQ HQDWMSGKEF KCKVNNKDLP APIERTISKP KGSVRAPQVY VLPPPEEEMT KKQVTLTCMV TDFMPEDIYV EWTNNGKTEL NYKNTEPVLD SDGSYFMYSK LRVEKKNWVE RNSYSCSVVH EGLHNHHTTK SFSRTPG (SEQ ID NO: 122)
[0107] In some embodiments, the anti-SIRP multimer comprises an anti-SIRP antibody comprising a VH comprising SEQ ID NO: 115 and a VL comprising SEQ ID NO: 116. In some embodiments, about 1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x compared to the amount of drug in plasma. To obtain a molar excess of anti-SIRP multimer ( For example, an anti-SIRP antibody) is added to a plasma sample (eg, a plasma sample obtained from a subject undergoing treatment with a drug).
[0108] In some embodiments, the anti-SIRP multimer comprises an anti-SIRP antibody that includes a heavy chain comprising SEQ ID NO: 119 and a light chain comprising SEQ ID NO: 118. In some embodiments, about 1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x compared to the amount of drug in plasma. To obtain a molar excess of anti-SIRP multimer ( For example, an anti-SIRP antibody) is added to a plasma sample (eg, a plasma sample obtained from a subject undergoing treatment with a drug).
[0109] In some embodiments, the anti-SIRP multimer comprises an anti-SIRP antibody that includes a heavy chain comprising SEQ ID NO: 117 and a light chain comprising SEQ ID NO: 118. In some embodiments, about 1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x compared to the amount of drug in plasma. To obtain a molar excess of anti-SIRP multimer ( For example, an anti-SIRP antibody) is added to a plasma sample (eg, a plasma sample obtained from a subject undergoing treatment with a drug).
[0110] In some embodiments, the anti-SIRP multimer comprises an anti-SIRP antibody that includes a heavy chain comprising SEQ ID NO: 120 and a light chain comprising SEQ ID NO: 121. In some embodiments, about 1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x compared to the amount of drug in plasma. To obtain a molar excess of anti-SIRP multimer ( For example, an anti-SIRP antibody) is added to a plasma sample (eg, a plasma sample obtained from a subject undergoing treatment with a drug).
[0111] Other exemplary anti-SIRP antibodies that may be included in the SIRP multimers used in the methods described herein (e.g., anti-SIRPα antibodies, anti-SIRPβ antibodies, and / or anti-SIRPγ antibodies that cross-react with SIRPα) or Drug binding fragments thereof are known in the art. Further details regarding such antibodies can be found, for example, in WO2018 / 057669;US-2018-0105600-A1;US20180312587;WO2018107058;WO2019023347;US20180037652;WO2018210795;WO2017178653;WO2018149 938; WO2017068164; and WO2016063233, the contents of which are is incorporated herein by reference. In some embodiments, the anti-SIRP antibody disclosed in one of the above references comprises a mouse Fc domain (or portion thereof). In some embodiments, the mouse Fc domain comprises the amino acid sequence set forth in any one of SEQ ID NOs: 81-83.
[0112] In some embodiments, the anti-SIRP multimers include the same anti-SIRP antibody (e.g., the same anti-SIRPα antibody, anti-SIRPα variant antibody, anti-SIRPβ variant antibody, anti-SIRPγ antibody, anti-SIRPγ variant antibody, or SIRPα, SIRPα SIRPβ variant, SIRPγ, and / or an antibody capable of cross-reacting with one or more of SIRPγ variant) or a drug-binding fragment thereof. In some embodiments, the anti-SIRP multimer is a homomultimer comprising monospecific bivalent anti-SIRP antibodies. In some embodiments, the SIRP multimer is a heteromultimer comprising at least two different anti-SIRP antibodies or drug binding fragments thereof in any combination. In some embodiments, the anti-SIRP multimer comprises a multispecific anti-SIRP antibody (i.e., a multispecific anti-SIRP antibody comprising a first VH / VL pair and a second VH / VL pair (first and second VH / VL pairs). The two VH / VL pairs contain different amino acid sequences, and the first and second VH / VL pairs each bind to the CD47 binding moiety of the drug.
[0113] In some embodiments, the anti-SIRP antibody or drug-binding fragment thereof is an anti-SIRP antibody, including, but not limited to, the exemplary multimerization domains described above for CD47 polypeptide monomers and SIRP polypeptide monomers. Contains the somatization domain.
[0114] In some embodiments, the anti-SIRP antibody or drug-binding fragment thereof comprises (eg, further comprises) an epitope tag. In some embodiments, the epitope tag facilitates multimerization of the anti-SIRP antibody (or drug binding fragment thereof). In some embodiments, the tag facilitates immobilization of the anti-SIRP antibody (or drug-binding fragment thereof) to a solid support (eg, bead, glass surface, etc.). Exemplary epitope tags include, but are not limited to, SEQ ID NOs: 7-32, described elsewhere herein.
[0115] In some embodiments, the anti-SIRP antibody (or drug-binding fragment thereof) comprises (eg, is attached to) a ligand. In some embodiments, the ligand is biotin. In some embodiments, the anti-SIRP antibody (or drug binding fragment thereof, eg, Fab or F(ab')2) comprises HHHHHHGLNDIFEAQKIEWHE (SEQ ID NO: 135) or GSGSHHHHHGLNDIFEAQKIEWHE (SEQ ID NO: 126). GLNDIFEAQKIEWHE (SEQ ID NO: 8), also known as AVITAG™, is specifically biotinylated by the E. coli biotin ligase BirA. In some embodiments, Fab or F(ab')2 comprises SEQ ID NOs: 131 and 132. In some embodiments, about 1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x compared to the amount of drug in plasma. To obtain any one of the following: anti-SIRP multimer ( For example, a Fab or F(ab')2 comprising SEQ ID NOs: 131 and 132) is added to a plasma sample (eg, a plasma sample obtained from a subject undergoing treatment with a drug).
[0116] In some embodiments, the anti-SIRP antibodies (or drug-binding fragments thereof) of the anti-SIRP multimer are linked, e.g., via a peptide bond, to form a linking chain of the anti-SIRP antibodies (or drug-binding fragments thereof). , are connected. In some embodiments, the anti-SIRP antibodies (or drug-binding fragments thereof) in the SIRP multimer are linked via a linker peptide. Exemplary linker peptides include those set forth in SEQ ID NOs: 85-109, 127-130, IEGR (SEQ ID NO: 141), IDGR (SEQ ID NO: 140), and those used with CD47 multimers and / or SIRP multimers. Other linkers include, but are not limited to (see above). In some embodiments, the anti-SIRP antibodies (or drug-binding fragments thereof) of the anti-SIRP multimer are linked via a linker peptide and at least one spacer. Exemplary peptide spacers include, but are not limited to, SEQ ID NOs: 52-70, and other spacers used with CD47 multimers and / or SIRP multimers (see above).
[0117] In some embodiments, the anti-SIRP multimer comprises at least one (eg, 1-100) anti-SIRP antibodies (or drug-binding fragments thereof) bound to a solid support. In some embodiments, the anti-SIRP antibody, or anti-SIRP antibody or drug-binding fragment thereof, is attached to a solid support via covalent bonding or non-covalent capture. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, the solid support comprises or is made from, for example, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride, or polypropylene. In some embodiments, the anti-SIRP multimer comprises an anti-SIRP antibody, or more than one anti-SIRP antibody (or drug-binding fragment thereof), and a solid support, wherein the anti-SIRP antibody, or anti-SIRP antibody or drug-conjugated fragment thereof, The fragment comprises an epitope tag or ligand (e.g., as described above), the capture agent is immobilized on a solid support, and the anti-SIRP antibody, or anti-SIRP antibody or drug-binding fragment thereof, is immobilized on a solid support. It is attached to the solid support through specific binding of the epitope tag or ligand by the immobilized capture agent. In some embodiments, the anti-SIRP antibody, or anti-SIRP antibody or drug binding fragment thereof, comprises SEQ ID NO: 111. In some embodiments, the ligand is biotin and the capture agent is streptavidin. In some embodiments, the anti-SIRP multimer (e.g., homomultimer or heteromultimer) comprises streptavidin conjugated to two, three, or four biotinylated anti-SIRP antibodies (or drug-binding fragments thereof). or contains avidin. In some embodiments, the anti-SIRP antibody (or drug binding fragment thereof) comprises SEQ ID NO: 111. In some embodiments, the anti-SIRP multimer comprises streptavidin or avidin linked to 2, 3, or 4 F(ab')2 fragments. In some embodiments, two or more of the F(ab')2 fragments include SEQ ID NO: 131 and SEQ ID NO: 132.
[0118] (c) Method for producing anti-SIRP multimers In some embodiments, an anti-SIRP multimer (e.g., a homomultimer comprising, e.g., two or more anti-SIRP antibodies (or drug-binding fragments thereof) linked via a peptide bond or a linker peptide) (or heteromultimers) are produced by recombinant host cells. Any of the methods described herein that use recombinant techniques to produce CD47 or SIRP multimers are also applicable to the production of anti-SIRP multimers, including anti-SIRP antibodies (or antigen-binding fragments thereof). Applicable.
[0119] In some embodiments, anti-SIRP multimers (e.g., homomultimers or heteromultimers) bind to one or more (e.g., 1-100) anti-SIRP antibodies (or drugs thereof) via non-covalent capture. binding fragment) to a solid support. In some embodiments, the solid support is gold nanospheres, gold nanoshells, magnetic beads, silica beads, dextran polymers, test tubes, slides, gel columns, or microtiter wells. In some embodiments, the anti-SIRP antibody or anti-SIRP antibody (or drug-binding fragment thereof) each comprises a ligand, the capture agent is immobilized on a solid support, and the anti-SIRP multimer comprises: Anti-SIRP antibodies, or anti-SIRP antibodies (or drug-binding fragments thereof), are produced by binding to a solid support via specific binding of the ligand by a capture agent that is immobilized on the solid support. In some embodiments, the ligand is biotin and the capture agent is streptavidin. In some embodiments, the anti-SIRP antibody(s) (or drug binding fragment thereof) comprises SEQ ID NO: 111 or SEQ ID NO: 126.
[0120] Any of the methods described elsewhere herein in which CD47 polypeptide monomers are attached to a solid support to generate CD47 multimers also binds anti-SIRP antibodies (or drug-binding fragments thereof). It can be applied to generate anti-SIRP multimers by binding to a solid support. For example, in some embodiments, the anti-SIRP multimer targets a host cell containing a nucleic acid encoding an anti-SIRP antibody (or drug-binding fragment thereof) comprising SEQ ID NO: 111 or SEQ ID NO: 126. Anti-SIRP antibodies (or drug-binding fragments thereof) are prepared by culturing them under appropriate conditions that cause expression of the anti-SIRP antibodies (or drug-binding fragments thereof). Anti-SIRP antibodies (or drug-binding fragments thereof) containing biotin receptor peptide amino acid sequences are biotinylated using E. coli biotin ligase (BirA). In some embodiments, anti-SIRP multimers are generated by attaching biotinylated anti-SIRP antibody(s) (or drug-binding fragment thereof) to a solid support on which streptavidin or avidin molecules are immobilized. Ru. In some embodiments, for example, an anti-SIRP multimer comprising one or more (e.g., 1-100) anti-SIRP antibodies (or drug-binding fragments thereof) bound to a streptavidin or avidin-conjugated solid support. (eg, homomultimers or heteromultimers). Exemplary streptavidin or avidin conjugate solid supports are described in further detail elsewhere herein. In some embodiments, an anti-SIRP multimer (e.g., a homomultimer or a heteromultimer) comprising streptavidin or avidin conjugated to two, three, or four biotinylated anti-SIRP antibodies (or drug-binding fragments thereof) body) is provided.
[0121] In some embodiments, anti-SIRP multimers are linked to one or more anti-SIRP antibodies (or (drug-binding fragments thereof), eg, to a solid support, or, eg, to each other.
[0122] The anti-SIRP multimers thus produced are then used in the methods provided herein to prevent interference by drugs that bind to CD47 in serological assays.
[0123] V. Exemplary Drugs The methods provided herein reduce (or, in some embodiments, eliminate) interference in serological assays. This is caused by the presence of a drug containing (i) an antibody Fc region and (ii) a moiety that binds human CD47 in a sample containing plasma or RBCs / platelets obtained from a subject undergoing treatment with the drug. . In some embodiments, the drug comprises an IgG Fc region, eg, a human IgG Fc region, eg, an IgG1, IgG2, or IgG4 Fc region. In some embodiments, the drug comprises a modified Fc region (e.g., a modified IgG Fc region), which has one or more amino acid substitution(s), deletion(s), insertion(s), N-terminal addition(s), and / or C-terminal addition(s). Exemplary Fc regions are described in WO2017177333; WO2014094122; US2015329616, WO2017 / 027422; US2017 / 0107270; and USP 10,259,859, the contents of which are incorporated herein by reference in their entirety.
[0124] In some embodiments, the moiety that binds human CD47 is wild-type SIRPα that lacks a transmembrane domain (eg, any extracellular domain of wild-type SIRPα that is capable of binding human CD47). In some embodiments, the moiety that binds human CD47 is a SIRPα variant that is capable of binding human CD47 and lacks a transmembrane domain. In some embodiments, the SIRPα variant has one or more amino acid substitution(s), deletion(s), insertion(s), N-terminal addition, as compared to the extracellular domain of wild-type SIRPα. (s), and / or C-terminal addition(s). In some embodiments, the SIRPα variant is a SIRPα-d1 domain variant. In some embodiments, the affinity of the SIRPα variant for human CD47 is higher than the affinity of wild-type SIRPα for human CD47.
[0125] In some embodiments, the moiety that binds human CD47 is wild-type SIRPγ that lacks a transmembrane domain (eg, any extracellular domain of wild-type SIRPγ that is capable of binding human CD47). In some embodiments, the moiety that binds human CD47 is a SIRPγ variant that is capable of binding human CD47 and lacks a transmembrane domain. In some embodiments, the SIRPγ variant has one or more amino acid substitution(s), deletion(s), insertion(s), N-terminal addition, as compared to the extracellular domain of wild-type SIRPγ. (s), and / or C-terminal addition(s). In some embodiments, the SIRPγ variant is a SIRPγ-d1 domain variant. In some embodiments, the affinity of the SIRPγ variant for human CD47 is higher than the affinity of wild-type SIRPγ for human CD47.
[0126] In some embodiments, the moiety that binds human CD47 is a SIRPβ variant that is capable of binding human CD47 and lacks a transmembrane domain. In some embodiments, the SIRPβ variant has one or more amino acid substitution(s), deletion(s), insertion(s), N-terminal addition, as compared to the extracellular domain of wild-type SIRPβ. (s), and / or C-terminal addition(s). In some embodiments, the SIRPβ variant is a SIRPβ-d1 domain variant.
[0127] Exemplary SIRPα, SIRPβ, and SIRPγ variants are known in the art and include WO2013 / 109752;US2015 / 0071905;USP9,944,911;WO2016 / 023040;WO2017 / 027422;US2017 / 0107270;USP10,259,859; US9845345;WO2016187226;US20180155405;WO2017177333;WO2014094122;US2015329616;US20180312563;WO2018176132;WO2018081898;WO2018081897;US2018 0141986A1; and EP3287470A1, the contents of which are incorporated herein by reference in their entirety.
[0128] In some embodiments of any of the above methods, the drug is an anti-CD47 antibody. In some embodiments, the anti-CD47 antibody is AO-176, CC-90002, Hu5F9-G4 (also referred to as 5F9), SHR-1603, NI-1701, SRF231, TJC4, or IBI188. For more information about these and other therapeutic anti-CD47 antibodies, please see WO2018175790A1;US20180142019;US20180171014;US20180057592;US20170283498,US9,518,116;US9,518,117;US20150274826;US2016013 7733;US9,221,908;US20140161799;US20160137734;WO2015191861;WO2014093678;WO2014123580;WO2013119714 ;US9,045,541;WO2016109415;WO2018183182;WO2018009499;WO2017196793;US9663575;US20140140989;WO2018237168;US20180037652;US20190023784;WO201 8095428;EP3411071;WO2019042285;WO2016081423;WO2011076781;WO2012172521;WO2014087248;US20140303354;WO2016156537;US20160289727;US201900624 28;US20180201677;US9352037;US20170044258 ;US9650441; and US20180105591.
[0129] VI. Exemplary serological assays for pre-transfusion testing Pre-transfusion testing is performed to ensure that the blood product intended for transfusion is compatible with the blood of the subject (i.e., the recipient of the transfusion). Pre-transfusion testing includes serological assays used to confirm ABO compatibility between donor and recipient blood, as well as the most clinically important assays that react with antigens on donor RBCs and / or donor platelets. Includes those used to detect RBC / platelet alloantibodies (see Technical Manual, 18th ed, AABB, Bethesda, MD, 2014). Other exemplary blood group antigens for which serological assays are performed to determine donor / recipient transfusion compatibility include, for example, Kell blood group antigens, Duffy blood group antigens, Knops blood group antigens, Cartwright blood blood group antigens, Scianna blood group antigens, Indian blood group antigens, rhesus blood group antigens, Dombrock blood group antigens, Landsteiner-Wiener blood group antigens, and VEL blood group antigens. The methods provided herein involve drug interference in many serological assays known in the art (e.g., interference by drugs that include (i) an antibody Fc region and (ii) a moiety that binds human CD47). reduce or prevent Exemplary serological assays in which this method can be used include, but are not limited to, those described in further detail below.
[0130] Typically, serological assays are performed, for example, on non-human cells from a subject in need of a blood transfusion (e.g., a subject undergoing treatment with a drug containing (i) an antibody Fc region and (ii) a moiety that binds human CD47). It is performed using samples containing hemolyzed blood, plasma (eg, plasma samples that have been anticoagulated in EDTA), clotted blood, or serum. Generally, the subject's ABO type and Rh type are first determined. The antibody screening method is then used to detect unexpected clinically important non-ABO blood group antibodies that may be present in the subject's plasma. If the screening test reveals the presence of such antibodies, an antibody identification panel is used to determine the specificity of the antibodies. After the specificity of the antibody has been determined, suitable ABO and Rh donor units are screened for the corresponding antigen. Units negative for that antigen are cross-matched with subjects requiring blood transfusions to ensure compatibility.
[0131] Serological assays can be performed in test tubes, on slides, on gel columns, or in microtiter well plates, and hemolysis and agglutination are signals indicating a positive (incompatible) test result. Aggregation, a reaction that reflects the ligation of neighboring RBCs coated with antibodies, can be scored visually and / or microscopically with the most commonly used test tube method on a scale of 0 to 4+. . A score of 0 indicates no reactivity and is characterized by smooth, easily dispersed cells. A score of 4+ indicates strong reactivity and is characterized by one solid agglomerate that does not easily disperse. A score of 1+, 2+, or 3+ indicates an intermediate level of reactivity, with higher scores characterized by progressively larger aggregate sizes. A similar result for agglutination scoring occurs when serological tests are performed using gel columns (gel cards) containing anti-IgG antibodies in the column or microtiter well plates (solid phase) containing bound red blood cell antigens. Principles can be applied. Various techniques are currently available for detecting antibody-RBC antigen interactions with varying sensitivities. In some embodiments, serological assays are performed manually. In some embodiments, serological assays are performed via automated machines.
[0132] For example, instant spin (IS) (also known as "instant spin crossmatching") is a method that uses e.g. It is an assay that requires mixing, immediately centrifuging the mixture for approximately 15-30 seconds at room temperature or 37 °C, as well as visually inspecting the tube for direct agglutination. Direct agglutination indicates that there is a strong interaction between antibodies in plasma and RBC surface antigens. Alternatively, the subject's plasma and reagent RBCs (i.e., RBCs known to express a particular cell surface antigen or group of cell surface antigens) and / or reagent platelets (i.e., a particular cell surface antigen or group of cell surface antigens) (known to express platelets) can be mixed, centrifuged, and directly visually assessed for aggregation.
[0133] Anti-human globulin (AHG) is used to detect antibody-bound RBCs that do not directly agglutinate. AHG is a secondary anti-human globulin antibody that is produced in another species. AHG reagents can be specific for a single class of human Ig (e.g., IgG) or multispecific, i.e., capable of binding multiple human Ig classes (e.g., IgG, IgM, IgA) and complement. be. AHG serum can be used in direct antiglobulin testing (DAT) and / or indirect antiglobulin testing (IAT). DAT demonstrates in vivo sensitization of red blood cells and is performed by directly testing washed patient red blood cell samples with AHG. IAT represents an in vitro reaction between red blood cells and antibodies. In IAT, serum (or plasma) is incubated with red blood cells, which are then washed to remove unbound globulin. The presence of agglutination upon addition of AHG indicates that the antibody is binding to the specific red blood cell antigen. Some methods include the addition of an enhancement reagent (enhancement), such as saline, albumin, low ionic strength saline (LISS), or polyethylene glycol (PEG), and then the sample is and then incubated at 37°C for 10-60 minutes. In some embodiments, the assay is a test tube assay. In some embodiments, the assay is a solid phase red blood cell adhesion assay (SPRCA).
[0134] ABO typing involves testing the recipient's red blood cells for the presence of A and B antigens (front test typing) using anti-A and anti-B antisera. Testing the recipient plasma for the presence of anti-A and anti-B using known type A and B red blood cells (Ula test typing) is also part of a routine ABO blood group test.
[0135] The Rh(D) type of a transfusion recipient is determined by testing the recipient's red blood cells with anti-D. ABO typing is usually tested using instant spin (IS).
[0136] Alloantibodies to antigens not present on the individual's red blood cells can develop in individuals who have been exposed to foreign red blood cell antigens through pregnancy or blood transfusion. To detect antibodies to non-A or B antigens, samples of patient plasma or serum are tested against selected commercially available type O red blood cells that express the majority of clinically important antigens other than A and B. will be tested.
[0137] If the antibody screen is positive, further serological testing is performed using an expanded panel of commercially available type O reagent RBCs to identify clinically significant antibodies. Then, once the specificity of the antibody is known, donor units must be screened for the corresponding antigen in order to select units lacking the antigen.
[0138] Phenotyping of recipient red blood cells may also be performed to determine which red blood cell antibodies an individual is likely to develop. Serological assays for RBC phenotyping involve mixing recipient cells with commercially available reagent antisera containing specific antibodies.
[0139] Unenhanced and enhanced IAT (eg, saline, LISS, PEG) are used for antibody detection and antibody identification.
[0140] "Crossmatch" refers to a method of confirming compatibility between a patient's blood (plasma) and donor red blood cells. Cross-matching is primarily meant to detect and prevent ABO mismatches. Serological crossmatch assays (either IS crossmatch or AHG phase crossmatch) involve direct mixing of donor red blood cells with recipient plasma and scoring of hemolysis and agglutination after immediate spin or AHG testing.
[0141] In some embodiments, serological assays are performed using gel cards. The principle of the gel card test and the detection of hemagglutination reactions are described in Lapierre, et al. (1990) “The gel test: a new way to detect red cells antigen-antibody reactions.” Transfusion, 30:109-113. based on the gel method. A plastic card is made up of multiple microtubes. Each microtube contains an incubator chamber at the top of the column. Each microtube within the card is prefilled with a buffered gel solution containing specific antibodies against RBC or platelet surface antigens. Aggregation occurs when the subject's RBCs or platelets react with the corresponding antibodies present in the gel solution. Alternatively, the microtube is filled with the subject's serum and agglutination occurs when reagent RBCs or reagent platelets react with antibodies present in the patient's serum or plasma. The gel column acts as a filter to trap aggregated red blood cells as they pass through the gel column during centrifugation of the card. The gel column separates aggregated red blood cells from non-agglutinated red blood cells based on size. Agglutinated red blood cells are trapped at the top of the gel column or along the gel column, and unagglutinated red blood cells reach the bottom of the microtube to form a pellet.
[0142] In some embodiments, the serological assay is a solid phase assay (e.g., a drug that binds to CD47 described herein, RBCs of interest, reagent RBCs, or antibodies to known RBC and / or platelet surface antigens). (a multimer is immobilized on a solid support) that reduces / reduces the interference of In some embodiments, serological assays are performed manually. In some embodiments, serological assays are performed using automated systems. In some embodiments, the automated system is a multiplexed high-throughput system that allows simultaneous analysis of multiple RBC, platelet, serum, or plasma samples obtained from different subjects. In some embodiments, the automated system is a multiplexed high-throughput system that allows simultaneous analysis of various serological assays using RBC, platelet, serum, or plasma samples obtained from a single subject. be. Automated blood analysis systems are typically microprocessor controlled instruments. Exemplary automated blood analysis systems include, for example, Immucor's NEO® system (ie, a solid phase platform) and Diagast's QWALYS® 3 system. Qwalys® is a fully automated red blood cell magnetization technology (EMT) system for ABO / D typing, Rh phenotyping, K typing, and antibody screening (ABS).
[0143] This specification is believed to be sufficient to enable one skilled in the art to practice the invention. Various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description and are within the scope of the appended claims. All publications, patents, and patent applications cited herein are incorporated by reference in their entirety for all purposes.
[0144] Each embodiment described herein may be combined with any other embodiment(s) unless explicitly indicated to the contrary. In particular, any feature or embodiment indicated as being preferred or advantageous may, unless expressly stated to the contrary, include any other feature(s) or embodiment(s) indicated as being preferred or advantageous. (can be combined with more than one).
Example
[0145] The following examples are included to provide those skilled in the art with a complete disclosure and description of how to make and use the invention, and are not intended to limit the scope of what the inventors regard as their invention. Nor is it intended that the following experiments represent all or the only experiments performed. Efforts have been made to ensure the accuracy of numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric.
[0146] Example 1: Preparation of an exemplary CD47 multimer Preparation of CD47 multimer B CD47 polypeptide monomer containing SEQ ID NO: 6 (see below) was transiently expressed in Expi293F cells, harvested, purified using Ni SEPHAROSE® 6 FAST FLOW chromatography resin, and size excluded. Purified by chromatography. QLLFNKTKSV EFTFSNDTVV IPCFVTNMEA QNTTEVYVKW KFKGRDIYTF DGALNKSTVP TDFSSAKIEV SQLLKGDASL KMDKSDAVSH TGNYTCEVTE LTREGETIIE LKYRVVSHHH HHHGLNDIFE AQKIEWHE (SEQ ID NO: 6)
[0147] Purified CD47 polypeptide monomers were biotinylated in vitro using the BirA biotinylation kit available from Avidity LLC. The in vitro biotinylation reaction mixture was then purified by size exclusion chromatography to separate the biotinylated CD47 polypeptide monomer from the excess biotin present in the mixture.
[0148] The biotinylated CD47 polypeptide monomer was then incubated with streptavidin protein at a molar ratio of biotinylated CD47 polypeptide monomer: streptavidin of 4.5:1 overnight at 4°C with gentle agitation. The reaction mixture is then purified by size exclusion chromatography to separate CD47 multimers (i.e., tetramerized biotinylated CD47 polypeptide monomers bound to streptavidin) from other species in the mixture. did. CD47 multimers (ie, tetramers) were confirmed by size exclusion chromatography against gel filtration standards.
[0149] Example 2: Preparation of exemplary anti-SIRP multimers Generation of anti-SIRP octamer (anti-SIRP multimer C) Anti-SIRP F(ab')2 containing a VH-CH1 sequence containing SEQ ID NO: 131 and a VL-CL sequence containing SEQ ID NO: 132 was prepared as follows. The C-terminus of SEQ ID NO: 131 includes SEQ ID NO: 126, which includes the hexahistidine peptide HHHHHH (SEQ ID NO: 7) and the 15 amino acid tag GLNDIFEAQKIEWHE (SEQ ID NO: 8). GLNDIFEAQKIEWHE (SEQ ID NO: 8), also known as AVITAG(TM). SEQ ID NO: 8 is specifically biotinylated with E. coli biotin ligase BirA. DVQLVESGGG VVRPGESLRL SCEASGFTFS SNAMSWVRQA PGKGLEWVAG ISSGSDTYYG DSVKGRLTIS RDNSKNILYL QMNSLTAEDT AVYYCARETW NHLFDYWGLG TLVTVSSAKT TAPSVYPLAP VCGDTTGSSV TLGCLVKGYF PEPVTLTWNS GSLSSGVHTF PAVLQSDLYT LSSSVTVTSS TWPSQS ITCN VAHPASSTKV DKKIEPRGPT IKPCPPCKCP GSGSHHHHHH GLNDIFEAQK IEWHE (SEQ ID NO: 131) ALTQPASVSA SPGETVEITC SGGSDSSYYY GWYQQKSPGS APVTVIYSDN KRPSNIPSRF SGSASGSTAT LTITGVRVED EAVYYCGGYD YSTYTNPFGA GTTLTVLRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC (Sequence number 132)
[0150] SEQ ID NOs: 131 and 132 were transiently expressed in Expi293 cells. Transfection supernatants were purified using Ni SEPHAROSE® 6 FAST FLOW chromatography resin and polished by size exclusion chromatography. Purified anti-SIRP(Fab')2 was biotinylated in vitro using the BirA biotinylation kit available from Avidity LLC. The in vitro biotinylation reaction mixture was then purified by size exclusion chromatography to separate the biotinylated anti-SIRP F(ab')2 from the excess biotin present in the mixture.
[0151] Next, biotinylated anti-SIRP F(ab')2 was added to the streptavidin protein in a molar ratio of 4.5:1 biotinylated anti-SIRP F(ab')2:streptavidin at 4°C with gentle stirring. Incubated with The reaction mixture was then purified by size exclusion chromatography to produce anti-SIRP F(ab')2 multimers (i.e., tetramerized biotinylated anti-SIRP F(ab')2 conjugated to streptavidin). was separated from other species in the mixture. Anti-SIRP F(ab')2 multimers (ie, octamers) were confirmed by size exclusion chromatography against gel filtration standards.
[0152] Generation of anti-SIRP multimer D The VH containing SEQ ID NO: 115, the VL containing SEQ ID NO: 116, and the anti-SIRP antibody containing the mouse Fc domain were transiently expressed in Expi293 cells. (SEQ ID NOs: 115 and 116 are provided below). Anti-SIRP antibodies were purified from cell culture supernatants via MabSelect LX and dialyzed into 1× phosphate buffered saline. DVQLVESGGG VVRPGESLRL SCAASGFTFS SNAMSWVRQA PGKGLEWLAG ISAGGSDTYY PASVKGRFTI SRDNSKNTLY LQMNTLTAED TAVYYCARET WNHLFDYWGL GTLVTVSS (SEQ ID NO: 115) ALTQPASVSA NPGETVKIAC SGGDYYSYYY GWYQQKAPGS ALVTVIYSDD KRPSDIPSRF SGSASGSTAT LTITGVRAED EAVYYCGGYD YSTYANAFGA GTTLTVL (SEQ ID NO: 116)
[0153] Example 3: In a given serological test using CD47 multimer B, anti-SIRP multimer C, or anti-SIRP multimer D, (i) the antibody Fc region and (ii) the portion that binds human CD47 Reduced drug interference, including: Experiments were conducted to assess whether CD47 multimer B, anti-SIRP multimer C, or anti-SIRP multimer D would reduce the interference of drug A in an indirect antiglobulin test (IAT) using a test tube method. Drug A is an exemplary CD47 binding drug that includes a SIRPα variant (i.e., a CD47 binding domain derived from human SIRPα) and an Fc variant derived from the Fc region of human immunoglobulin IgG1; have previously been shown to interfere with transfusion assays (see Kim et al. (2020) Transfusion.1-9).
[0154] To prepare donor red blood cells (RBCs) and donor plasma, HemeQC whole blood samples (commercially available from Bio-Rad) from donors of various blood types were spun at 1000xg for 10 min at room temperature to separate plasma from red blood cells. . The pelleted red blood cells were then resuspended at 3.4% in MLB2 LISS (low ionic strength solution).
[0155] To perform the assay, 100 μL of 130 nM (10 μg / mL) drug A was added at a 1:2 dilution starting at 20 times the molar concentration of drug A in each donor plasma, CD47 multimer B, anti-SIRP multimer C, co-incubated with anti-SIRP multimer D or CD47 polypeptide monomer (SEQ ID NO: 6) for 10 minutes at room temperature (RT). Next, 100 μL of each titration condition was added to the capture well containing 50 μL of 3.4% RBC from each donor and incubated for 45 minutes at 37°C. Wells were then washed with PBS and spun three times at 400 x g for 5 min at room temperature. Two drops of AHG anti-IgG (ie, anti-human globulin IgG) were added to each well and centrifuged at 800×g for 30 seconds. The reaction mixture was gently agitated to pellet the cells before image acquisition. Capture wells containing PBS served as negative controls for the assay, and wells containing only Drug A served as positive controls.
[0156] Figure 4 shows the results of IAT using a test tube assay using blood samples from donors with blood / plasma type AsubB RhD+. Figure 5 shows the results of IAT using a test tube assay using blood samples from donors with RBC type / plasma type O RhD+R1r DCcee containing anti-Fy. Figure 6 shows the results of IAT using a test tube assay using blood samples from blood type / plasma type A1 RhD-rr ccee donors with anti-D. Different molar titrations (20x, 10x, 5x, 2.5x, 1.25x, 0.63x, 0.31x) of CD47 multimer B, anti-SIRP multimer C, anti-SIRP multimer D, and CD47 monomer (i.e., drug A comparison) was tested.
[0157] Aggregation was observed across all molar titrations in IAT assays using CD47 polypeptide monomers (see Figures 4-6). In contrast, no aggregation was observed in IAT assays with addition of at least 5× molar ratio of CD47 multimer B, 2.5× molar ratio of anti-SIRP multimer C, and 2.5× molar ratio of anti-SIRP multimer D. . CD47 multimer B, anti-SIRP multimer C, and anti-SIRP multimer D demonstrated the ability to prevent drug A from interfering with blood typing when using AHG anti-IgG reagent in a test tube assay. .
[0158] Subsequent experiments are performed to assess whether CD47 multimer B, anti-SIRP multimer C, or anti-SIRP multimer D alleviates the interference of drug A in the solid-phase red blood cell adhesion assay (SPRCA).
[0159] In summary, 50 μL of 130 nM (10 μg / mL) drug A was added to CD47 multimer B, anti-SIRP multimer C, or anti-SIRP multimer at a 1:2 dilution starting from a 20× molar concentration of drug A in PBS. Co-incubated with body D for 10 minutes at room temperature (RT). 50 μL of each titration condition was then added to Capture R wells, which were coated with red blood cell membranes prepared from a pooled suspension of equal proportions of red blood cells from two type O donors. Two drops of capture LISS reagent were then added to each well and the wells were incubated for 45 minutes at 37°C. Wells were then washed 6 times with PBS. After washing, one drop of Capture-R Ready Indicator Red cells was added to each well. Wells were spun at 450xg for 1 minute before images were acquired.
[0160] Aggregation was observed in SPRCA assays using CD47 polypeptide monomers (see Figure 7). In contrast, in SPRCA assays supplemented with at least 0.31x molar ratio of CD47 multimer B, 0.31x molar ratio of anti-SIRP multimer C, or 0.63x molar ratio of anti-SIRP multimer D, interference by drug A was Not observed. CD47 multimer B, anti-SIRP multimer C, and anti-SIRP multimer D have the ability to prevent drug A from interfering with blood typing when using AHG anti-IgG reagents in solid-phase red blood cell adhesion assays. Proven.
[0161] Example 4: Preparation of exemplary anti-SIRP multimer E and anti-SIRP multimer F Anti-SIRP multimer E comprises a heavy chain comprising SEQ ID NO: 117 and a light chain comprising SEQ ID NO: 118. Anti-SIRP multimer F comprises a heavy chain comprising SEQ ID NO: 120 and a light chain comprising SEQ ID NO: 121. DVQLVESGGG VVRPGESLRL SCAASGFTFS SNAMSWVRQA PGKGLEWLAG ISAGGSDTYY PASVKGRFTI SRDNSKNTLY LQMNTLTAED TAVYYCARET WNHLFDYWGL GTLVTVSSAK TTPPSVYPLA PGSAAQTNSM VTLGCLVKGY FPEPVTVTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVPS STWPSETVTC NVA HPASSTK VDKKIVPRDC GCKPCICTVP EVSSVFIFPP KPKDVLTITL TPKVTCVVVD ISKDDPEVQF SWFVDDVEVH TAQTQPREEQ FASTFRSVSE LPIMHQDWLN GKEFKCRVNS AAFPAPIEKT ISKTKGRPKA PQVYTIPPPK EQMAKDKVSL TCMITDFFPE DITVEWQWNG QPAENYKNTQ P IMDTDGSYF IYSKLNVQKS NWEAGNTFTC SVLHEGLHNH HTEKSLSHSP G (SEQ ID NO: 117) ALTQPASVSA NPGETVKIAC SGGDYYSYYY GWYQQKAPGS ALVTVIYSDD KRPSDIPSRF SGSASGSTAT LTITGVRAED EAVYYCGGYD YSTYANAFGA GTTLTVLGQP KSSPSVTLFP PSSEELETNK ATLVCTITDF YPGVVTVDWK VDGTPVTQGM ETTQPSKQSN NKYMASSYLT LTARAWERHS SYSCQVTHEG HTVEKSLSRA DCS (Sequence number 118) DVQLVESGGG VVRPGESLRL SCAASGFTFS SYAMSWVRQA PGKGLEWLAG ISAGGSDTYY IDSVKGRFTI SRDNPKNSLY LQMSSLTAED TAVYYCARET WNHLFDYWGL GTLVTVSSAK TTPPSVYPLA PGSAAQTNSM VTLGCLVKGY FPEPVTVTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVPS STWPSETVTC NVA HPASSTK VDKKIVPRDC GCKPCICTVP EVSSVFIFPP KPKDVLTITL TPKVTCVVVD ISKDDPEVQF SWFVDDVEVH TAQTQPREEQ FASTFRSVSE LPIMHQDWLN GKEFKCRVNS AAFPAPIEKT ISKTKGRPKA PQVYTIPPPK EQMAKDKVSL TCMITDFFPE DITVEWQWNG QPAENYKNTQ P IMDTDGSYF IYSKLNVQKS NWEAGNTFTC SVLHEGLHNH HTEKSLSHS PG (SEQ ID NO: 120) ALTQPASVSA NPGETVKITC SGGDYYSTYY AWYQQKSPGS APVTVIHSDD KRPSDIPSRF SGSASGSAAT LIITGVRVED EAVYYCGGYD GRTYINTFGA GTTLTVLGQP KSSPSVTLFP PSSEELETNK ATLVCTITDF YPGVVTVDWK VDGTPVTQGM ETTQPSKQSN NKYMASSYLT LTARAWERHS SYSCQVTHEG HT VEKSLSRA DCS (Sequence number 121)
[0162] To prepare anti-SIRP multimer E, SEQ ID NOs: 117 and 118 were expressed in 293FS cells. Multimers were purified using standard protein A affinity chromatography methods and dialyzed into 1× phosphate buffered saline according to the manufacturer's recommended protocols (MabSelect LX, Cytiva). Anti-SIRP multimer F was prepared by expressing SEQ ID NOs: 120 and 121 in 293F cells and purifying the multimer described for anti-SIRP multimer E.
[0163] Example 5: Reducing interference of drugs containing (i) the antibody Fc region and (ii) a moiety that binds human CD47 in routine serological tests using anti-SIRP multimer E or anti-SIRP multimer F. . Experiments were conducted to compare the extent to which anti-SIRP multimer E and anti-SIRP multimer F can alleviate the interference of drug A in a solid phase red blood cell adhesion assay (SPRCA). The SPRCA assay was performed as described in Example 3. As shown in Figure 8, anti-SIRP multimer E and anti-SIRP multimer F both equally interfered with drug A by adding at least a 1.25-fold molar ratio compared to drug A. It is possible to reduce this.
[0164] Example 6: Preparation of an exemplary anti-SIRP multimer G Anti-SIRP multimer G includes a heavy chain comprising SEQ ID NO: 119 and a light chain comprising SEQ ID NO: 118. DVQLVESGGG VVRPGESLRL SCAASGFTFS SNAMSWVRQA PGKGLEWLAG ISAGGSDTYY PASVKGRFTI SRDNSKNTLY LQMNTLTAED TAVYYCARET WNHLFDYWGL GTLVTVSSAK TTAPSVYPLA PVCGDTTGSS VTLGCLVKGY FPEPVTLTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVTS STWPSQSITC N VAHPASSTK VDKKIEPRGP TIKCPPCKC PAPNLLGGPS VFIFPPKIKD VLMISLSPIV TCVVVDVSED DPDVQISWFV NNVEVHTAQT QTHREDYNST LRVVSALPIQ HQDWMSGKEF KCKVNNKDLP APIERTISKP KGSVRAPQVY VLPPPEEEMT KKQVTLTCMV TDFMPEDIYV EWTNNGKTEL NYKNTEPVLD SDGSYFMYSK LRVEKKNWVE RNSYSCSVVH EGLHNHHTTK SFSRTPG (SEQ ID NO: 119) ALTQPASVSA NPGETVKIAC SGGDYYSYYY GWYQQKAPGS ALVTVIYSDD KRPSDIPSRF SGSASGSTAT LTITGVRAED EAVYYCGGYD YSTYANAFGA GTTLTVLGQP KSSPSVTLFP PSSEELETNK ATLVCTITDF YPGVVTVDWK VDGTPVTQGM ETTQPSKQSN NKYMASSYLT LTARAWERHS SYSCQVTHEG HTVEKSLSRA DCS (Sequence number 118)
[0165] To prepare anti-SIRP multimer G, SEQ ID NOs: 118 and 119 were expressed in recombinant host cells. Multimers were purified using standard methods.
[0166] Example 7: Drug A interferes with blood typing assays performed using various platforms. Based on previous results regarding the potential for Drug A to interfere with RBC antibody screening (see e.g. Kim et al. (2020) Transfusion.1-9;doi:10.1111 / trf.16009), binding to red blood cell surface antigens Drug A was spiked into normal pooled plasma that was confirmed to be free of antibodies. Plasma samples from patients used in this study were collected as part of routine care at the hospital. The final concentrations of Drug A were 0.1, 1, 10, 100, 1000, and 2000 μg / mL, and Immucor in solid phase using Bio-Rad antibody screening cells I and II (Table 1) in gel card format. For antibody screening cells I, II, and III, test this using Diagast's automated high-throughput Qwalys3 system (Table 3) using Diagast's automated high-throughput NEO® system (Table 2). did. As shown in Tables 1-3, aggregation reactivity ranged from 2+ to 4+ (on a scale of 0 to 4+) and was observed across drug A concentrations tested. This suggests that binding of Drug A to RBCs and interaction of the Fc portion of Drug A with the AHG reagent interferes with the assay using the above format. Reagents were used according to the manufacturer's protocols. Bio-Rad's reagent information includes antibody screening I and II cells: ID-DiaCell I-II, ID cell-derived rr phenotype: ID-DiaPanel: gel card: ID card. Gel card assay was performed according to the manufacturer's protocol. Briefly, 50 μL of 0.8% RBC suspension and 25 μL of plasma were utilized, incubated for 15 minutes at 37° C., and centrifuged for 10 minutes on a Bio-Rad ID-Centrifuge. The plasma was pooled from patients confirmed to be type AB and did not contain alloantibodies.
table 1
[0167] Reagents for the NEO® solid phase platform for routine use in the NEO® system were supplied by Immucor. Reagents included Capture-R Ready-Screen (I and II). Reagent red blood cells (in the form of red blood cell stroma) were bound to the test wells during manufacture. The plasma volume per well was 25 μL. [Table 2]
[0168] Certain reagents used in the QWALYS3 platform (Erythrocyte Magnetization Technology (EMT)) were supplied by Diagast. One reagent was Hemascreen I-II-III (1% magnetized red blood cells). The red blood cell and plasma volumes per well were 15 and 15 μL, respectively. [Table 3]
[0169] The data in Table 1 shows that Drug A produced a 2+ to 3+ agglutination reactivity in the gel card test (Bio-Rad). Comparable agglutination reactivity was observed in gel card tests using D--, i.e., RBCs with significantly reduced CD47 expression, and in gel cards using rr, i.e., RBCs with high CD47 expression. . The data in Tables 2 and 3 show that drug A increases 4+ agglutination reactivity in high-throughput solid-phase tests (NEO®, QWALYS®) even at very low concentrations of drug A. Indicates that something has happened.
[0170] Example 8: Reducing the interference of drugs containing (i) antibody Fc regions and (ii) a moiety that binds human CD47 in routine serological tests using anti-SIRP multimer G. Experiments were conducted to assess the extent to which anti-SIRP multimer G alleviates drug A interference in gel card assays. Assays were performed as described in Example 7. In one series of experiments, multimer G was added to plasma samples to obtain final concentrations of 0.1, 1, 10, 100, 1000, or 2000 μg / mL. Gel card serological assay was performed. As shown in Table 4, a 6-fold molar excess of anti-SIRP multimer G compared to drug A reduces the interference of drug A when drug A is present at a concentration of 2000 μg / mL in the sample. did. A 4-fold molar excess of anti-SIRP multimer G compared to drug A reduced the interference of drug A when drug A was present at a concentration of 1000 μg / mL in the sample. A 3-fold molar excess of anti-SIRP multimer G reduced the interference of drug A when drug A was present in the sample at a concentration of 0.1-100 μg / mL. [Table 4]
[0171] Drug A is then added to plasma samples containing anti-Jka or anti-E antibodies (i.e., known alloantibodies) to a final concentration of drug A of 0.1, 1, 10, 100, 1000, or 2000 μg / mL was obtained. Gel Gard assay was performed. As shown in Table 5, drug A, present at a concentration of 2000 μg / mL in plasma, interfered with the detection of anti-Jka and anti-E alloantibodies. Multimer G neutralized the interference of drug A without interfering with the detection of anti-Jka and anti-E alloantibodies. [Table 5]
[0172] The data in Tables 4 and 5 support the conclusion that anti-SIRP multimer G reduces the interference caused by drug A present in plasma. Such mitigation allows detection of alloantibodies in plasma by gel card assays.
[0173] Example 9: Interference in serological assays caused by drugs comprising (i) an antibody Fc region and (ii) a moiety that binds human CD47 can be alleviated by using multimeric G across a variety of platforms. Further studies were conducted to evaluate the extent to which Drug A interferes with serological assays in test tube and gel card formats. Plasma samples (AB inactive plasma) were spiked with drug A to obtain final concentrations of drug A of 31.25, 125, 500, or 2000 μg / ml. In test tube studies, the presence of drug A in plasma at concentrations of 500 μg / ml and 2000 μg / ml resulted in a strongly positive direct antiglobulin test (DAT). Drug A at the tested concentrations of 31.25 μg / ml and 2000 μg / ml did not interfere with ABO typing (front and back tests) or RhD typing. Due to the positive DAT, interference was observed in RhD typing with respect to the weak D in AHG. Drug A at all concentrations tested (31.25 μg / ml, 125 μg / ml, 500 μg / ml, and 2000 μg / ml) interfered with antibody screening during the initial spin (where traditional ABO incompatibility was tested). but caused strong agglutination with all cells in the indirect antiglobulin test (IAT) using PEG and both AHG reagents tested (Immucor and Ortho). In the gel card test, drug A caused strong positive agglutination with all cells tested at all concentrations of drug A (i.e., 31.25 μg / ml, 125 μg / ml μg / ml, 500 μg / ml, and 2000 μg / ml). Ta. (Data not shown).
[0174] Multimer G (100 mg / ml) was added to plasma at a ratio of 1:10 (v / v, multimer G: plasma) and incubated for 15 minutes at room temperature, resulting in a concentration of 500 μg / ml in plasma. Any drug A interference present was removed. See Table 6A. Multimer G (100 mg / ml) was added to plasma at a ratio of 1:10 (v / v, multimer G: plasma) and incubated for up to 60 min at room temperature or 37°C. The antibody screen is positive if the interference is partially attenuated (“vw+” or “very weak+”, which falls between 0 and 1+) and is present in the plasma at a concentration of 2000 μg / ml. (“w1+” or “weak 1+”, which falls within 0 to 1+). See Table 6B. Reactivity in antibody screening decreased significantly, but remained weakly positive in tests with PEG-IAT and LISS-IAT. See Table 6C. [Table 6] [Table 7] [Table 8]
[0175] The use of multimeric G did not affect the reactivity of homologous anti-D by LISS or PEGIAT or gel card tests. See Table 7. The use of multimeric G did not affect the reactivity of homologous anti-K by LISS or PEGIAT or gel card tests. See Table 8. [Table 9] [Table 10]
[0176] As shown in Table 9A, Drug A causes aggregation in LISSIAT, PEGIAT, and gel card test formats. [Table 11]
[0177] The following results are shown in Table 9B: Multimer G (150 mg / ml) was added to plasma at a ratio of 1:10 (v / v, Multimer G: plasma). After 30 minutes of incubation, the interference by drug A was completely alleviated by multimer G in the LISS IAT test when present at 750 μg / ml or 1000 μg / ml in plasma. After 30 minutes of incubation, interference by drug A was virtually abolished by multimeric G in the LISS IAT test when present in plasma at 1250 μg / ml, 1500 μg / ml, or 2000 μg / ml (micro+ reactivity). After 30 minutes of incubation, interference by Drug A at all concentrations tested (750 μg / mL, 1000 μg / mL, 1250 μg / mL, 1500 μg / mL, and 2000 μg / mL) was significantly reduced by multimer G in the PEG IAT test. Significantly decreased (1+ or micro+). After 30 minutes of incubation, interference by drug A was completely alleviated by multimer G in the IgG gel test when present at 750 μg / ml, 1000 μg / ml, or 1250 μg / ml in plasma. After 30 minutes of incubation, interference by drug A was significantly reduced by multimer G in IgG gel tests when present at 1500 μg / ml or 2000 μg / ml in plasma (1+ or + / −). [Table 12]
[0178] The results below are shown in Table 9C. Multimer G (150 mg / ml) was added to plasma at a ratio of 1:10 (v / v, multimer G: plasma). After 60 minutes of incubation, interference by drug A was completely alleviated by multimeric G in the LISS IAT test when present at 750 μg / ml, 1000 μg / ml, or 1250 μg / ml in plasma. After 60 minutes of incubation, the interference by drug A was virtually abolished by multimer G in the LISS IAT test (micro+reactivity) when present at 1500 μg / mL in plasma. Mitigation by multimeric G of interference by drug A, when present at 2000 μg / mL in plasma, was not evaluated in the LISS IAT test in this experiment. After 60 minutes of incubation, drug A interference was virtually abolished by multimeric G in the PEG IAT test when present in plasma at 750 μg / mL, 1000 μg / mL, 1250 μg / mL, or 1500 μg / mL. (micro+reactive). Mitigation by multimeric G of interference by drug A, when present at 2000 μg / mL in plasma, was not evaluated in the PEG IAT test in this experiment. After 60 minutes of incubation, interference by drug A was completely alleviated by multimer G when present at 750 μg / mL or 1000 μg / mL in plasma and at 1250 μg / mL or 1500 μg / mL in plasma. , was significantly reduced (weak + or + / -) by multimeric G in the IgG gel test. Mitigation by multimeric G of drug A interference was not evaluated in the IgG gel test when present at 2000 μg / mL in plasma. [Table 13]
Claims
1. 1. A method for reducing drug interference in a serological assay using reagent red blood cells (RBCs) or reagent platelets, the method comprising: (a) adding an anti-SIRP multimer that binds to the drug and blocks the drug from binding to the reagent RBCs or the reagent platelets to a plasma sample from a subject undergoing treatment with the drug; and (b) after step (a), performing a serological assay on the plasma sample using the reagent RBCs or the reagent platelets; Including, The drug comprises (i) a human antibody Fc region or a variant thereof, and (ii) a portion that binds to human CD47; The method, wherein the anti-SIRP multimer comprises one or more anti-SIRP antibodies or drug-binding fragments thereof.
2. 2. The method of claim 1, wherein the anti-SIRP multimer comprises 1 to 100 anti-SIRP antibodies or drug-binding fragments thereof.
3. 3. The method of claim 1 or 2, wherein the anti-SIRP multimer comprises a wild-type SIRPα, a SIRPα variant, a SIRPβ variant, a wild-type SIRPγ, a SIRPγ variant, or an anti-SIRP antibody or drug-binding fragment thereof that binds to any two or more of these.
4. the anti-SIRP multimer comprising: (a) a heavy chain variable domain comprising SEQ ID NO: 46 (V H ) and a light chain variable domain (V L ), (b) a heavy chain variable domain comprising SEQ ID NO: 48 (V H ) and a light chain variable domain (V L ), (c) a heavy chain variable domain comprising SEQ ID NO: 50 (V H ) and a light chain variable domain (V L ), (d) a heavy chain variable domain comprising SEQ ID NO: 113 (V H ) and a light chain variable domain (V L ), (e) a heavy chain variable domain comprising SEQ ID NO: 115 (V H ) and a light chain variable domain (V L ), and / or (f) a heavy chain variable domain comprising SEQ ID NO: 133 (V H ) and a light chain variable domain (V L ), The method of any one of claims 1 to 3, comprising an anti-SIRP antibody or drug-binding fragment thereof comprising:
5. The method of any one of claims 1 to 4, wherein the anti-SIRP multimer comprises a full-length anti-SIRP antibody.
6. 6. The method of claim 5, wherein the anti-SIRP antibody comprises a mouse Fc domain.
7. The method of claim 6, wherein the mouse Fc domain comprises an amino acid sequence set forth in any one of SEQ ID NOs: 81-83.
8. The anti-SIRP antibody, (a) a heavy chain comprising SEQ ID NO: 117 and a light chain comprising SEQ ID NO: 118; (b) a heavy chain comprising SEQ ID NO: 119 and a light chain comprising SEQ ID NO: 118; (c) a heavy chain comprising SEQ ID NO: 120 and a light chain comprising SEQ ID NO: 121; or (d) a heavy chain comprising SEQ ID NO: 122 and a light chain comprising SEQ ID NO: 121; The method according to any one of claims 5 to 7, comprising:
9. The drug-binding fragment of the anti-SIRP antibody is a Fab, Fab', F(ab') 2 5. The method of claim 1, wherein the antibody is a Fab'-SH, Fv, diabody, one-arm antibody, scFv, scFv-Fc, single domain antibody, or single heavy chain antibody.
10. The method of claim 9 , wherein the drug-binding fragment comprises F(ab′)2, and the F(ab′)2 comprises SEQ ID NOs: 131 and 132.
11. The method of any one of claims 1 to 10, wherein the anti-SIRP antibody or drug-binding fragment thereof comprises an epitope tag or a ligand.
12. The method of claim 11, wherein the epitope tag comprises any one of SEQ ID NOs: 7-32 and 126, or the ligand comprises biotin.
13. 12. The method of claim 11, wherein the epitope tag comprises HHHHHHGLNDIFEAQKIEWHE (SEQ ID NO: 135) or GSGSHHHHHGLNDIFEAQKIEWHE (SEQ ID NO: 126).
14. The method of any one of claims 1 to 13, wherein the one or more anti-SIRP antibodies or drug-binding fragments thereof are bound to a solid support.
15. 15. The method of claim 14, wherein the solid support is a gold nanosphere, a gold nanoshell, a magnetic bead, a silica bead, a dextran polymer, a test tube, a slide, a gel column, or a microtiter well.
16. 16. The method of claim 14 or 15, wherein each of the one or more anti-SIRP antibodies or drug-binding fragments thereof comprises an epitope tag or a ligand, a capture agent that specifically binds to the epitope tag or ligand is immobilized on the solid support, and the anti-SIRP antibody or drug-binding fragment thereof is bound to the solid support by specific binding of the epitope tag or ligand by the capture agent.
17. The method of claim 16, wherein the ligand is biotin and the capture agent is streptavidin.
18. 14. The method of any one of claims 1-13, wherein the anti-SIRP multimer comprises streptavidin or avidin bound to two, three, or four biotinylated anti-SIRP antibodies, or fragments thereof.
19. 19. The method of claim 18, wherein the anti-SIRP multimer comprises the streptavidin or the avidin bound to two, three, or four biotinylated F(ab')2 fragments, and two or more of the biotinylated F(ab')2 fragments comprise SEQ ID NOs: 131 and 132.
20. The method of any one of claims 1 to 19, wherein the anti-SIRP multimer is a homomultimer.
21. The method of any one of claims 1 to 19, wherein the anti-SIRP multimer is a heteromultimer.
22. 22. The method of any one of claims 1 to 21, wherein the portion of the drug that binds to human CD47 comprises wild-type SIRPα, a SIRPα variant, or a fragment of the wild-type SIRPα or the SIRPα variant.
23. 23. The method of claim 22, wherein the portion of the drug that binds to human CD47 comprises a SIRPa variant, the SIRPa variant comprising one or more amino acid substitution(s), insertion(s), deletion(s), N-terminal extension(s), and / or C-terminal extension(s) compared to the wild-type SIRPa.
24. 24. The method of claim 22 or 23, wherein the portion of the drug that binds to human CD47 comprises a fragment of the SIRPα variant, the fragment comprising the extracellular domain of the SIRPα variant.
25. 22. The method of any one of claims 1-21, wherein the portion of the drug that binds to human CD47 comprises wild-type SIRPγ, a SIRPγ variant, or a fragment of the wild-type SIRPγ or the SIRPγ variant.
26. 26. The method of claim 25, wherein the portion of the drug that binds to human CD47 comprises the SIRPy variant, wherein the SIRPy variant comprises one or more amino acid substitution(s), insertion(s), deletion(s), N-terminal extension(s), C-terminal extension(s), or any combination thereof, compared to the wild-type SIRPy.
27. 27. The method of claim 25 or 26, wherein the portion of the drug that binds to human CD47 comprises a fragment of the SIRPy variant, the fragment comprising the extracellular domain of the SIRPy variant.
28. 22. The method of any one of claims 1 to 21, wherein the portion of the drug that binds to human CD47 comprises a SIRPβ variant or a fragment of the SIRPβ variant.
29. 29. The method of claim 28, wherein the portion of the drug that binds to human CD47 comprises the SIRPβ variant, wherein the SIRPβ variant comprises one or more amino acid substitution(s), insertion(s), deletion(s), N-terminal extension(s), C-terminal extension(s), or any combination thereof, compared to a wild-type SIRPβ.
30. 30. The method of claim 28 or 29, wherein the portion of the drug that binds to human CD47 comprises a fragment of the SIRPβ variant, the fragment comprising the extracellular domain of the SIRPβ variant.
31. The method of any one of claims 1 to 30, wherein the antibody Fc region of the drug is a human IgG Fc region or a variant thereof.
32. 32. The method of claim 31 , wherein the human IgG Fc region is a human IgG1, IgG2, or IgG4 Fc region, or a variant of a human IgG1, IgG2, or IgG4 Fc region.
33. The serological assay (a) ABO / Rh typing assay; (b) Instant spin (IS) assay; (c) a direct antiglobulin (DAT) assay using a multispecific reagent that detects IgG and complement C3; or (d) Direct Antiglobulin (DAT) Assay Using Monospecific Reagents to Detect Complement C3 The method according to any one of claims 1 to 32, wherein
34. The method of any one of claims 1 to 33, wherein the serological assay is a PEG-enhanced serological assay.
35. 34. The method of claim 33, wherein the serological assay is an eluate test performed after the DAT assay.
36. The serological assay (a) Test tube assay; (b) solid phase red blood cell assay (SPRCA); (c) a gel card assay; or (d) Solid-phase assay The method according to any one of claims 1 to 32, wherein
